Document:

Exhibit 10.15

   

  Form of Warrant

   

  NEITHER THIS SECURITY NOR THE SECURITIES
      AS TO WHICH THIS SECURITY MAY BE EXERCISED HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION
      OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”),
      AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
      TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
      WITH APPLICABLE STATE SECURITIES LAWS AS EVIDENCED BY A LEGAL OPINION OF COUNSEL TO THE TRANSFEROR TO SUCH EFFECT, THE SUBSTANCE OF WHICH
      SHALL BE REASONABLY ACCEPTABLE TO THE COMPANY. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED
      IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.

   

  COMMON
      STOCK PURCHASE WARRANT

   

  GZ6G TECHNOLOGIES CORP.

   

  Warrant
      Shares: 10,487

  Date
      of Issuance: November 19, 2021 (“Issuance Date”)

   

  This
      COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for services provided according to Finder’s Fee Agreement
      dated September 7, 2021, J.H. Darbie & Co., Inc., a New York corporation (including any permitted and registered assigns, the “Holder”),
      is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time during the
      Exercise Period (as defined below), to purchase from GZ6G Technologies Corp., a Nevada corporation (the “Company”), up to
      10,487 shares of Common Stock (as defined below) (the “Warrant Shares”) (whereby such number may be adjusted from time to
      time pursuant to the terms and conditions of this Warrant) at the Exercise Price per share then in effect. This Warrant is issued by
      the Company as of the date hereof in connection with that certain securities purchase agreement dated November 19, 2021, by and among
      the Company and the Introduced Party (as defined in the Finder’s Fee Agreement).

   

  Terms
      used in this Warrant shall have the meanings set forth in Section 13 below. For purposes of this Warrant, the term “Exercise Price”
      shall mean $2.88, subject to adjustment as provided herein (including but not limited to cashless exercise), and the term “Exercise
      Period” shall mean the period commencing on the Issuance Date and ending on 5:00 p.m. eastern standard time on the date which is
      5 years after the Issuance Date.

   

  1. EXERCISE
        OF WARRANT.

   

  (a) Mechanics
        of Exercise. Subject to the terms and conditions hereof, the rights represented by this Warrant may be exercised in whole or in
      part at any time or times during the Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit B (the
      “Exercise Notice”), of the Holder’s election to exercise this Warrant. The Holder shall not be required to deliver
      the original Warrant in order to effect an exercise hereunder. Partial exercises of this Warrant resulting in purchases of a portion
      of the total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares
      purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. On or before the second Trading Day
      (the “Warrant Share Delivery Date”) following the date on which the Holder sent the Exercise Notice to the Company or
      the Company’s transfer agent, and upon receipt by the Company of payment to the Company of an amount equal to the applicable
      Exercise Price multiplied by the number of Warrant Shares as to which all or a portion of this Warrant is being exercised (the
      “Aggregate Exercise Price” and together with the Exercise Notice, the “Exercise Delivery Documents”) in cash
      or by wire transfer of immediately available funds (or by cashless exercise, in which case there shall be no Aggregate Exercise
      Price provided), the Company shall (or direct its transfer agent to) issue and dispatch by overnight courier to the address as
      specified in the Exercise Notice, a certificate, registered in the Company’s share register in the name of the Holder or its
      designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise (or deliver such shares
      of Common Stock in electronic format if requested by the Holder). Upon delivery of the Exercise Delivery Documents, the Holder shall
      be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant
      has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is
      submitted in connection with any exercise and the number of Warrant Shares represented by this Warrant submitted for exercise is
      greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable and in no
      event later than three Business Days after any exercise and at its own expense, issue a new Warrant (in accordance with Section 6)
      representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under this Warrant,
      less the number of Warrant Shares with respect to which this Warrant is exercised.

   

  

  
  
    1

  

  
     

  

  
   

  Form of Warrant

   

  If
      the Company fails to cause its transfer agent to transmit to the Holder the respective shares of Common Stock by the respective Warrant
      Share Delivery Date, then the Holder shall have, in addition to all other rights and remedies at law or otherwise, the right to rescind
      such exercise in Holder’s sole discretion, and such failure shall be deemed an event of default under the Note.

   

  If
      the Market Price of one share of Common Stock is greater than the Exercise Price, the Holder may elect to receive Warrant Shares pursuant
      to a cashless exercise, in lieu of a cash exercise, equal to the value of this Warrant determined in the manner described below (or of
      any portion thereof remaining unexercised) by surrender of this Warrant and a Notice of Exercise, in which event the Company shall issue
      to Holder a number of Common Stock computed using the following formula:

   

  X
      = Y (A-B)

  

       A

   

  	Where  	X =	the number of Shares to be issued to Holder.
	 	 	 
		Y =	the number of Warrant Shares that the Holder elects to purchase under this Warrant (at the date of such calculation).
	 	 	 
	 	A =	the Market Price (at the date of such calculation).
	 	 	 
	 	B =	Exercise Price (as adjusted to the date of such calculation).

   

  (b) No
        Fractional Shares. No fractional shares shall be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant
      hereto. All Warrant Shares (including fractions) issuable upon exercise of this Warrant may be aggregated for purposes of determining
      whether the exercise would result in the issuance of any fractional share. If, after aggregation, the exercise would result in the issuance
      of a fractional share, the Company shall, in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction
      a sum in cash equal to the product resulting from multiplying the then-current fair market value of a Warrant Share by such fraction.

   

  
  
    2

  

  
     

  

  
   

  Form of Warrant

   

  (c) Holder’s
        Exercise Limitations. Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this
      Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section 1 or otherwise, to the extent
      that after giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with
      the Holder’s affiliates (the “Affiliates”), and any other Persons acting as a group together with the Holder or any
      of the Holder’s Affiliates (such Persons, “Attribution Parties”)), would beneficially own in excess of the Beneficial
      Ownership Limitation (as defined below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned
      by the Holder and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
      respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon
      (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution
      Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the Company (including,
      without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation
      contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties. Except as set forth in the preceding
      sentence, for purposes of this Section 1(c), beneficial ownership shall be calculated in accordance with Section 13(d) of the Exchange
      Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Holder is solely responsible for
      any schedules required to be filed in accordance therewith. In addition, a determination as to any group status as contemplated above
      shall be determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes
      of this Section 1(c), in determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding
      shares of Common Stock as reflected in (A) the Company’s most recent periodic or annual report filed with the Commission, as the
      case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the Transfer
      Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the Company shall
      within two Trading Days confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding. In any case,
      the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of securities
      of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number
      of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation” shall be 4.99% of the number of
      shares of the Common Stock outstanding at the time of the respective calculation hereunder. The limitations contained in this paragraph
      shall apply to a successor holder of this Warrant.

   

  2. ADJUSTMENTS.
      The Exercise Price and the number of Warrant Shares shall be adjusted from time to time as follows:

   

  (a) Distribution
        of Assets. If the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets)
      to holders of shares of Common Stock, by way of return of capital or otherwise (including without limitation any distribution of cash,
      stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement or other similar
      transaction) (a “Distribution”), at any time after the issuance of this Warrant, then, in each such case:

   

  (i) any
      Exercise Price in effect immediately prior to the close of business on the record date fixed for the determination of holders of shares
      of Common Stock entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to
      a price determined by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale Price of the
      shares of Common Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined in
      good faith by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator of which shall
      be the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and

  
  
    3

  

  
     

  

  
   

  Form of Warrant

   

  (ii) the
      number of Warrant Shares shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately
      prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive
      the Distribution multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided, however, that
      in the event that the Distribution is of shares of common stock of a company (other than the Company) whose common stock is traded on
      a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”), then the Holder
      may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant Shares, the terms
      of which shall be identical to those of this Warrant, except that such warrant shall be exercisable into the number of shares of Other
      Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the Holder exercised this Warrant
      immediately prior to such record date and with an aggregate exercise price equal to the product of the amount by which the exercise price
      of this Warrant was decreased with respect to the Distribution pursuant to the terms of the immediately preceding clause (i) and the
      number of Warrant Shares calculated in accordance with the first part of this clause (ii).

   

  (b) Anti-Dilution
        Adjustments to Exercise Price. If the Company or any Subsidiary thereof, as applicable, at any time while this Warrant is outstanding,
      shall sell or grant any option to purchase, or sell or grant any right to reprice, or otherwise dispose of or issue (or announce any
      offer, sale, grant or any option to purchase or other disposition) any Common Stock or securities entitling any person or entity to acquire
      shares of Common Stock (upon conversion, exercise or otherwise) (including but not limited to the price at which Common Stock is issuable
      under the Note), at an effective price per share less than the then Exercise Price (such lower price, the “Base Share Price”
      and such issuances collectively, a “Dilutive Issuance”) (if the holder of the Common Stock or Common Stock Equivalents so
      issued shall at any time, whether by operation of purchase price adjustments, elimination of an applicable floor price for any reason
      in the future (including but not limited to the passage of time or satisfaction of certain condition(s)), reset provisions, floating
      conversion, exercise or exchange prices or otherwise, or due to warrants, options or rights per share which are issued in connection
      with such issuance, be entitled or potentially entitled to receive shares of Common Stock at an effective price per share which is less
      than the Exercise Price at any time while such Common Stock or Common Stock Equivalents are in existence, such issuance shall be deemed
      to have occurred for less than the Exercise Price on such date of the Dilutive Issuance (regardless of whether the Common Stock or Common
      Stock Equivalents are (i) subsequently redeemed or retired by the Company after the date of the Dilutive Issuance or (ii) actually converted
      or exercised at such Base Share Price), then the Exercise Price shall be reduced at the option of the Holder and only reduced to equal
      the Base Share Price. Such adjustment shall be made whenever such Common Stock or Common Stock Equivalents are issued, regardless of
      whether the Common Stock or Common Stock Equivalents are (i) subsequently redeemed or retired by the Company after the date of the Dilutive
      Issuance or (ii) actually converted or exercised at such Base Share Price by the holder thereof (for the avoidance of doubt, the Holder
      may utilize the Base Share Price even if the Company did not actually issue shares of its common stock at the Base Share Price under
      the respective Common stock Equivalents). The Company shall notify the Holder in writing, no later than the Trading Day following the
      issuance of any Common Stock or Common Stock Equivalents subject to this Section 2(b), indicating therein the applicable issuance price,
      or applicable reset price, exchange price, conversion price and other pricing terms (such notice the “Dilutive Issuance Notice”).
      For purposes of clarification, whether or not the Company provides a Dilutive Issuance Notice pursuant to this Section 2(b), upon the
      occurrence of any Dilutive Issuance, after the date of such Dilutive Issuance the Holder is entitled to receive a number of Warrant Shares
      based upon the Base Share Price regardless of whether the Holder accurately refers to the Base Share Price in the Notice of Exercise.

   

  

  
  
    4

  

  
     

  

  
   

  Form of Warrant

   

  Subdivision
        or Combination of Common Stock. If the Company at any time on or after the Issuance Date subdivides (by any stock split, stock
      dividend, recapitalization or otherwise) one or more classes of its outstanding shares of Common Stock into a greater number of
      shares, the Exercise Price in effect immediately prior to such subdivision will be proportionately reduced and the number of Warrant
      Shares will be proportionately increased. If the Company at any time on or after the Issuance Date combines (by combination, reverse
      stock split or otherwise) one or more classes of its outstanding shares of Common Stock into a smaller number of shares, the
      Exercise Price in effect immediately prior to such combination will be proportionately increased and the number of Warrant Shares
      will be proportionately decreased. Any adjustment under this Section 2(c) shall become effective at the close of business on the
      date the subdivision or combination becomes effective. Each such adjustment of the Exercise Price shall be calculated to the nearest
      one-hundredth of a cent. Such adjustment shall be made successively whenever any event covered by this Section 2(c) shall
      occur.

   

  3. FUNDAMENTAL
        TRANSACTIONS. If, at any time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or into another
      entity and the Company is not the surviving entity (such surviving entity, the “Successor Entity”), (ii) the Company effects
      any sale of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer
      (whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant to which holders of Common
      Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or property and the holders of at least
      50% of the Common Stock accept such offer, or (iv) the Company effects any reclassification of the Common Stock or any compulsory share
      exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other
      than as a result of a subdivision or combination of shares of Common Stock) (in any such case, a “Fundamental Transaction”),
      then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive the number of shares of Common Stock of
      the Successor Entity or of the Company and any additional consideration (the “Alternate Consideration”) receivable upon or
      as a result of such reorganization, reclassification, merger, consolidation or disposition of assets by a holder of the number of shares
      of Common Stock for which this Warrant is exercisable immediately prior to such event (disregarding any limitation on exercise contained
      herein solely for the purpose of such determination). For purposes of any such exercise, the determination of the Exercise Price shall
      be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect
      of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the Exercise Price among the Alternate
      Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders
      of Common Stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder
      shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental
      Transaction. To the extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction shall
      issue to the Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant
      into Alternate Consideration.

   

  4. NON-CIRCUMVENTION.
      The Company covenants and agrees that it will not, by amendment of its certificate of incorporation, bylaws or through any reorganization,
      transfer of assets, consolidation, merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action,
      avoid or seek to avoid the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out
      all the provisions of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality
      of the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this
      Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that the
      Company may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant, and (iii)
      shall, for so long as this Warrant is outstanding, have authorized and reserved, free from preemptive rights, one and a half (1.5) times
      the number of shares of Common Stock into which the Warrants are then exercisable into to provide for the exercise of the rights represented
      by this Warrant (without regard to any limitations on exercise).

   

  5. WARRANT
        HOLDER NOT DEEMED A STOCKHOLDER. Except as otherwise specifically provided herein, this Warrant, in and of itself, shall not
      entitle the Holder to any voting rights or other rights as a stockholder of the Company. In addition, nothing contained in this
      Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or
      otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by creditors of the
      Company.

   

  

  
  
    5

  

  
     

  

  
   

  Form of Warrant

   

  6. REISSUANCE.

   

  (a) Lost,
        Stolen or Mutilated Warrant. If this Warrant is lost, stolen, mutilated or destroyed, the Company will, on such terms as to indemnity
      or otherwise as it may reasonably impose (which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new
      Warrant of like denomination and tenor as this Warrant so lost, stolen, mutilated or destroyed.

   

  (b) Issuance
        of New Warrants. Whenever the Company is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant
      shall be of like tenor with this Warrant, and shall have an issuance date, as indicated on the face of such new Warrant which is the
      same as the Issuance Date.

   

  7. TRANSFER.
      This Warrant shall be binding upon the Company and its successors and assigns and shall inure to be the benefit of the Holder and its
      successors and assigns. Notwithstanding anything to the contrary herein, the rights, interests or obligations of the Company hereunder
      may not be assigned, by operation of law or otherwise, in whole or in part, by the Company without the prior signed written consent of
      the Holder, which consent may be withheld at the sole discretion of the Holder (any such assignment or transfer shall be null and void
      if the Company does not obtain the prior signed written consent of the Holder). This Warrant or any of the severable rights and obligations
      inuring to the benefit of or to be performed by Holder hereunder may be assigned by Holder to a third party, in whole or in part, without
      the need to obtain the Company’s consent thereto.

   

  8. NOTICES.
      Whenever notice is required to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance
      with the notice provisions contained in the Purchase Agreement. The Company shall provide the Holder with prompt written notice (i) immediately
      upon any adjustment of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment and (ii) at least 20
      days prior to the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon
      the shares of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities directly or indirectly
      convertible into or exercisable or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common
      Stock or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each
      case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the Holder.

   

  9. AMENDMENT
        AND WAIVER. The terms of this Warrant may be amended or waived (either generally or in a particular instance and either retroactively
      or prospectively) only with the written consent of the Company and the Holder.

   

  10. GOVERNING
        LAW AND VENUE. This Warrant shall be governed by and construed in accordance with the laws of the State of Nevada without regard
      to principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by
      this Warrant shall be brought only in the state courts located in the Commonwealth of Massachusetts or federal courts located in
      Commonwealth of Massachusetts. The parties to this Warrant hereby irrevocably waive any objection to jurisdiction and venue of any
      action instituted hereunder and shall not assert any defense based on lack of jurisdiction or venue or based upon forum non
        conveniens. EACH PARTY HEREBY IRREVOCABLY WAIVES ANY RIGHT IT MAY HAVE TO, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE
        ADJUDICATION OF ANY DISPUTE HEREUNDER OR UNDER ANY OTHER TRANSACTION DOCUMENT ENTERED INTO IN CONNECTION WITH OR ARISING OUT OF THIS
        AGREEMENT, ANY OTHER TRANSACTION DOCUMENT OR ANY TRANSACTION CONTEMPLATED HEREBY OR THEREBY. The prevailing party shall be
      entitled to recover from the other party its reasonable attorney’s fees and costs. In the event that any provision of this Warrant
      or any other agreement delivered in connection herewith is invalid or unenforceable under any applicable statute or rule of law,
      then such provision shall be deemed inoperative to the extent that it may conflict therewith and shall be deemed modified to conform
      with such statute or rule of law. Any such provision which may prove invalid or unenforceable under any law shall not affect the
      validity or enforceability of any other provision of any agreement. Each party hereby irrevocably waives personal service of process
      and consents to process being served in any suit, action or proceeding in connection with this Agreement or any other Transaction
      Document by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party
      at the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient
      service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in
      any other manner permitted by law.

   

  

  
  
    6

  

  
     

  

  
   

  Form of Warrant

   

  11. PIGGYBACK
        REGISTRATION RIGHTS. The Company hereby grants to the Buyer the registration rights set forth on Exhibit D hereto.

   

  12. ACCEPTANCE.
      Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

   

  13. CERTAIN
        DEFINITIONS. For purposes of this Warrant, the following terms shall have the following meanings:

   

   (a) “Nasdaq” means www.Nasdaq.com.

   

  (b) “Closing
        Sale Price” means, for any security as of any date, (i) the last closing trade price for such security on the Principal Market,
      as reported by Nasdaq, or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade
      price, then the last trade price of such security prior to 4:00 p.m., New York time, as reported by Nasdaq, or (ii) if the foregoing
      does not apply, the last trade price of such security in the over-the-counter market for such security as reported by Nasdaq, or (iii)
      if no last trade price is reported for such security by Nasdaq, the average of the bid and ask prices of any market makers for such security
      as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for a security on a particular date on any of the foregoing
      bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and
      the Holder. All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination or other similar
      transaction during the applicable calculation period.

   

  (c) “Common
        Stock” means the Company’s common stock, and any other class of securities into which such securities may hereafter be
      reclassified or changed.

   

  (d) “Common
        Stock Equivalents” means any securities of the Company that would entitle the holder thereof to acquire at any time Common
      Stock, including without limitation any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible
      into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

   

   (e) [Intentionally Omitted].

   

  (f) “Person”
      and “Persons” means an individual, a limited liability company, a partnership, a joint venture, a corporation, a trust, an
      unincorporated organization, any other entity and any governmental entity or any department or agency thereof.

   

  (g) “Principal
        Market” means the primary national securities exchange on which the Common Stock is then traded.

   

  (h) “Market
        Price” means the highest traded price of the Common Stock during the one hundred and fifty Trading Days prior to the date of
      the respective Exercise Notice.

   

  

  
  
    7

  

  
     

  

  
   

  Form of Warrant

   

  (i) “Trading
        Day” means (i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the Common
      Stock is not then listed or quoted and traded on any national securities exchange, then a day on which trading occurs on any over-the-counter
      markets, or (iii) if trading does not occur on the over-the-counter markets, any Business Day.

   

  *
      * * * * * *

   

  

  
  
     

  

  
     

  

  
   

  

  Form of Warrant

   

  IN
      WITNESS WHEREOF, the Company has caused this Warrant to be duly executed as of the Issuance Date set forth above.

   

  

  	 	GZ6G Technologies Corp.
	 	 	 
	 	By: 	 
	 	Name:  	Coleman Smith
	 	Title: 	CEO

   

  

  
  
    8

  

  
     

  

  
   

  Form of Warrant

   

  EXHIBIT
        B

   

  NOTICE
      OF EXERCISE

   

  (To
      be executed by the registered holder to exercise this Common Stock Purchase Warrant)

   

  THE
      UNDERSIGNED holder hereby exercises the right to purchase of the shares of Common Stock (“Warrant Shares”) of GZ6G Technologies
      Corp., a Nevada corporation (the “Company”), evidenced by the attached copy of the Common Stock Purchase Warrant (the “Warrant”).
      Capitalized terms used herein and not otherwise defined shall have the respective meanings set forth in the Warrant.

    

  		1.	Form of Exercise Price. The Holder intends that payment of
            the Exercise Price shall be made as (check one):

   

  		☐	a cash exercise with respect to Warrant Shares; or

   

  		☐	by cashless exercise pursuant to the Warrant.

    

  		2.	Payment of Exercise Price. If cash exercise is selected
            above, the holder shall pay the applicable Aggregate Exercise Price in the sum of $ to the Company in accordance with the terms of the Warrant.

    

  		3.	Delivery of Warrant Shares. The Company shall deliver to the
            holder Warrant Shares in accordance with the terms of the Warrant.

   

  Date:
      ___________________________

   

  	 	 	 
	 	(Print Name of Registered Holder)
	 	 	 
	 	By:	      
	 	Name: 	 
	 	Title:	 

   

  

  
  
    9

  

  
     

  

  
   

  Form of Warrant

   

  EXHIBIT
        C

   

  ASSIGNMENT
      OF WARRANT

   

  (To
      be signed only upon authorized transfer of the Warrant)

   

  FOR
      VALUE RECEIVED, the undersigned hereby sells, assigns, and transfers unto the right to purchase ______________________ shares of
      common stock of GZ6G Technologies Corp., to which the within Common Stock Purchase Warrant relates and appoints                                           , as attorney-in-fact, to transfer said right on the books of GZ6G Technologies Corp.
      with full power of
      substitution and re-substitution in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects
      by the terms and conditions of the within Warrant.

   

  	Dated:
            __________________________	 
	 	 
	 	 
	 	(Signature)
	 	 
	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	 	 
	 	(Social Security or Tax Identification No.)

   

  *
      The signature on this Assignment of Warrant must correspond to the name as written upon the face of the Common Stock Purchase Warrant
      in every particular without alteration or enlargement or any change whatsoever. When signing on behalf of a corporation, partnership,
      trust, or other entity, please indicate your position(s) and title(s) with such entity.

   

  

  
  
    10

  

  
     

  

  
   

  Form of Warrant

   

  EXHIBIT
        D

   

  REGISTRATION
      RIGHTS

   

  All
      of the shares into which the Warrant is exercisable into will be deemed “Registrable Securities” subject to the provisions
      of this Exhibit C.

   

  		1.	Piggy-Back Registration.

   

  1.1 Piggy-Back
      Rights. If at any time on or after the date of the Closing the Company proposes to file any Registration Statement under the 1933 Act
      (a “Registration Statement”) with respect to any offering of equity securities, or securities or other obligations exercisable
      or exchangeable for, or convertible into, equity securities, by the Company for its own account or for shareholders of the Company for
      their account (or by the Company and by shareholders of the Company), other than a Registration Statement (i) filed in connection with
      any employee stock option or other benefit plan on Form S-8, (ii) for a dividend reinvestment plan or (iii) in connection with a merger
      or acquisition, then the Company shall (x) give written notice of such proposed filing to the holders of Registrable Securities appearing
      on the books and records of the Company as such a holder as soon as practicable but in no event less than ten (10) days before the anticipated
      filing date of the Registration Statement, which notice shall describe the amount and type of securities to be included in such Registration
      Statement, the intended method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the
      offering, and (y) offer to the holders of Registrable Securities in such notice the opportunity to register the sale of such number of
      Registrable Securities as such holders may request in writing within three (3) days following receipt of such notice (a “Piggy-Back
      Registration”). The Company shall cause such Registrable Securities to be included in such registration and shall cause the managing
      underwriter or underwriters of a proposed underwritten offering to permit the Registrable Securities requested to be included in a Piggy-Back
      Registration on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of
      such Registrable Securities in accordance with the intended method(s) of distribution thereof. All holders of Registrable Securities
      proposing to distribute their securities through a Piggy- Back Registration that involves an underwriter or underwriters shall enter
      into an underwriting agreement in customary form with the underwriter or underwriters selected for such Piggy-Back Registration.

   

  1.2 Withdrawal.
      Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable Securities in any
      Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration
      Statement. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written
      contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement.
      Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders of Registrable Securities in connection
      with such Piggy-Back Registration as provided in Section

  1.5
      below.

   

  1.3 The
      Company shall notify the holders of Registrable Securities at any time when a prospectus relating to such holder’s Registrable
      Securities is required to be delivered under the 1933 Act, upon discovery that, or upon the happening of any event as a result of
      which, the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or
      omits to state any material fact required to be stated therein or necessary to make the statements therein not misleading in light
      of the circumstances then existing. At the request of such holder, the Company shall also prepare, file and furnish to such holder a
      reasonable number of copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter
      delivered to the purchasers of the Registrable Securities, such prospectus shall not include an untrue statement of a material fact
      or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading in light
      of the circumstances then existing. The holders of Registrable Securities shall not to offer or sell any Registrable Securities
      covered by the Registration Statement after receipt of such notification until the receipt of such supplement or
      amendment.

   

  

  
  
    11

  

  
     

  

  
   

  Form of Warrant

   

  1.4 The
      Company may request a holder of Registrable Securities to furnish the Company such information with respect to such holder and such holder’s
      proposed distribution of the Registrable Securities pursuant to the Registration Statement as the Company may from time to time reasonably
      request in writing or as shall be required by law or by the SEC in connection therewith, and such holders shall furnish the Company with
      such information.

   

  1.5 All
      fees and expenses incident to the performance of or compliance with this Exhibit D by the Company shall be borne by the Company
      whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the
      foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and
      expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the
      SEC, (B) with respect to filings required to be made with any trading market on which the Common Stock is then listed for trading,
      (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
      without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of
      the Registrable Securities) and (D) with respect to any filing that may be required to be made by any broker through which a holder
      of Registrable Securities intends to make sales of Registrable Securities with the FINRA, (ii) printing expenses, (iii) messenger,
      telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) 1933 Act liability insurance, if the
      Company so desires such insurance, (vi) fees and expenses of all other persons or entities retained by the Company in connection
      with the consummation of the transactions contemplated by this Exhibit D and (vii) reasonable fees and disbursements of a single
      special counsel for the holders of Registrable Securities (selected by holders of the majority of the Registrable Securities
      requesting such registration). In addition, the Company shall be responsible for all of its internal expenses incurred in connection
      with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses
      of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses
      incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event
      shall the Company be responsible for any broker or similar commissions of any holder of Registrable Securities.

   

  1.6 The
      Company and its successors and assigns shall indemnify and hold harmless the Buyer, each holder of Registrable Securities, the
      officers, directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent
      role of a person holding such titles, notwithstanding a lack of such title or any other title) of each of them, each individual or
      entity who controls the Buyer or any such holder of Registrable Securities (within the meaning of Section 15 of the 1933 Act or
      Section 20 of the 1934 Act) and the officers, directors, members, stockholders, partners, agents and employees (and any other
      individuals or entities with a functionally equivalent role of a person holding such titles, notwithstanding a lack of such title or
      any other title) of each such controlling individual or entity (each, an “Indemnified Party”), to the fullest extent
      permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without
      limitation, reasonable attorneys’ fees) and expenses (collectively, “Losses”), as incurred, arising out of or
      relating to (1) any untrue or alleged untrue statement of a material fact contained in a Registration Statement, any related
      prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of
      or relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements
      therein (in the case of any such prospectus or supplement thereto, in light of the circumstances under which they were made) not
      misleading or (2) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act or any state securities law, or
      any rule or regulation thereunder, in connection with the performance of its obligations under this Exhibit D, except to the extent,
      but only to the extent, that (i) such untrue statements or omissions are based upon information regarding the Buyer or such holder
      of Registrable Securities furnished to the Company by such party for use therein. The Company shall notify the Buyer and each holder
      of Registrable Securities promptly of the institution, threat or assertion of any proceeding arising from or in connection with the
      transactions contemplated by this Exhibit D of which the Company is aware.

   

  

  
  
    12

  

  
     

  

  
   

  Form of Warrant

   

  1.7 If
      the indemnification under Section 1.6 is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless for
      any Losses, then the Company shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is appropriate
      to reflect the relative fault of the Company and Indemnified Party in connection with the actions, statements or omissions that resulted
      in such Losses as well as any other relevant equitable considerations. The relative fault of the Company and Indemnified Party shall
      be determined by reference to, among other things, whether any action in question, including any untrue or alleged untrue statement of
      a material fact or omission or alleged omission of a material fact, has been taken or made by, or relates to information supplied by,
      the Company or the Indemnified Party, and the parties’ relative intent, knowledge, access to information and opportunity to correct
      or prevent such action, statement or omission. The amount paid or payable by a party as a result of any Losses shall be deemed to include
      any reasonable attorneys’ or other fees or expenses incurred by such party in connection with any proceeding to the extent such
      party would have been indemnified for such fees or expenses if the indemnification provided for in Section 1.6 was available to such
      party in accordance with its terms. It is agreed that it would not be just and equitable if contribution pursuant to this Section 1.7
      were determined by pro rata allocation or by any other method of allocation that does not take into account the equitable considerations
      referred to in the immediately preceding sentence. Notwithstanding the provisions of this Section 1.7, neither the Buyer nor any holder
      of Registrable Securities shall be required to contribute, in the aggregate, any amount in excess of the amount by which the net proceeds
      actually received by such party from the sale of all of their Registrable Securities pursuant to such Registration Statement or related
      prospectus exceeds the amount of any damages that such party has otherwise been required to pay by reason of such untrue or alleged untrue
      statement or omission or alleged omission.

   

  [End
        of Exhibit D]

   

  

  
  
    13Exhibit
        10.16

   

  SECURITIES
      PURCHASE AGREEMENT

   

  This
      SECURITIES PURCHASE AGREEMENT (the “Agreement”), dated as of December 16, 2021, by and between GZ6G TECHNOLOGIES
        CORP., a Nevada corporation, with headquarters located at 8925 West Post Road, Suite 102, Las Vegas, NV 89148 (the “Company”),
      and TALOS VICTORY FUND, LLC, a Delaware limited liability company, with its address at 348 Cambridge Street #101, Woburn, MA 01801
      (the “Buyer”).

   

  WHEREAS:

   

  A. The
      Company and the Buyer are executing and delivering this Agreement in reliance upon the exemption from securities registration afforded
      by Section 4(a)(2) of the Securities Act of 1933, as amended (the “1933 Act”) and Rule 506(b) promulgated by the United States
      Securities and Exchange Commission (the “SEC”) under the 1933 Act;

   

  B. Buyer
      desires to purchase from the Company, and the Company desires to issue and sell to the Buyer, upon the terms and conditions set forth
      in this Agreement, a promissory note of the Company, in the aggregate principal amount of $560,000.00 (as the principal amount thereof
      may be increased pursuant to the terms thereof, and together with any note(s) issued in replacement thereof or as a dividend thereon
      or otherwise with respect thereto in accordance with the terms thereof, in the form attached hereto as Exhibit A, the “Note”),
      convertible into shares of common stock, $0.001 par value per share, of the Company (the “Common Stock”), upon the terms
      and subject to the limitations and conditions set forth in such Note; and

   

  C. The
      Buyer wishes to purchase, upon the terms and conditions stated in this Agreement, such principal amount of the Note as is set forth immediately
      below its name on the signature pages hereto; and

   

  D. The
      Company wishes to issue a common stock purchase warrant to purchase 560,000 shares of Common Stock (the “Warrant”) to the
      Buyer as additional consideration for the purchase of the Note, which shall be earned in full as of the Closing Date, as further provided
      herein.

   

  NOW
        THEREFORE, in consideration of the foregoing and of the agreements and covenants herein contained, and for other good and valuable
      consideration, the receipt and sufficiency of which is hereby acknowledged, the Company and the Buyer hereby agree as follows:

   

  1. Purchase
        and Sale of Note.

   

  a. Purchase
        of Note. On the Closing Date (as defined below), the Company shall issue and sell to the Buyer, and the Buyer agrees to purchase
      from the Company, the Note, as further provided herein. As used in this Agreement, the term “business day” shall mean any
      day other than a Saturday, Sunday, or a day on which commercial banks in the city of New York, New York are authorized or required by
      law or executive order to remain closed.

   

  b. Form
        of Payment. On the Closing Date: (i) the Buyer shall pay the purchase price of$ 504,000.00 (the “Purchase Price”)
      for the Note, to be issued and sold to it at the Closing (as defined below), by wire transfer of immediately available funds to the
      Company, in accordance with the Company’s written wiring instructions, against delivery of the Note, and (ii) the Company
      shall deliver such duly executed Note and Warrant on behalf of the Company, to the Buyer, against delivery of such Purchase Price.
      On the Closing, the Buyer shall withhold a non-accountable sum of $7,000.00 from the Purchase Price to cover the Buyer’s legal
      fees in connection with the transactions contemplated by this Agreement.

   

  c. Closing
        Date. Subject to the satisfaction (or written waiver) of the conditions thereto set forth in Section 6 and Section 7 below, the date
      and time of the issuance and sale of the Note pursuant to this Agreement (the “Closing Date”) shall be on the date that the
      Purchase Price for the Note is paid by Buyer pursuant to terms of this Agreement.

   

  d. Closing.
      The closing of the transactions contemplated by this Agreement (the “Closing”) shall occur on the Closing Date at such location
      as may be agreed to by the parties (including via exchange of electronic signatures).

   

  

  
  
    1

  

  
     

  

  
   

  e. Warrant.
      On or before the Closing Date, the Company shall issue the Warrant to the Buyer pursuant to the terms of contained therein.

   

  2. Buyer’s
        Representations and Warranties. The Buyer represents and warrants to the Company as of the Closing Date that:

   

  a. Investment
        Purpose. As of the Closing Date, the Buyer is purchasing the Note and Warrant (the Note, Warrant, shares of Common Stock issuable
      upon conversion of or otherwise pursuant to the Note (the “Conversion Shares”), and shares of Common Stock issuable upon
      exercise of or otherwise pursuant to the Warrant (the “Exercise Shares”) shall collectively be referred to herein as the
      “Securities”) for its own account and not with a present view towards the public sale or distribution thereof, except pursuant
      to sales registered or exempted from registration under the 1933 Act; provided, however, that by making the representations
      herein, the Buyer does not agree to hold any of the Securities for any minimum or other specific term and reserves the right to dispose
      of the Securities at any time in accordance with or pursuant to a registration statement or an exemption under the 1933 Act.

   

  b. Accredited
        Investor Status. The Buyer is an “accredited investor” as that term is defined in Rule 501(a) of Regulation D (an “Accredited
      Investor”).

   

  c. Reliance
        on Exemptions. The Buyer understands that the Securities are being offered and sold to it in reliance upon specific exemptions from
      the registration requirements of United States federal and state securities laws and that the Company is relying upon the truth and accuracy
      of, and the Buyer’s compliance with, the representations, warranties, agreements, acknowledgments and understandings of the Buyer
      set forth herein in order to determine the availability of such exemptions and the eligibility of the Buyer to acquire the Securities.

   

  d. Information.
      The Buyer and its advisors, if any, have been, and for so long as the Note remains outstanding will continue to be, furnished with
      all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities
      which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remains
      outstanding will continue to be, afforded the opportunity to ask questions of the Company regarding its business and affairs. Notwithstanding
      the foregoing, the Company has not disclosed to the Buyer any material nonpublic information regarding the Company or otherwise and will
      not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the
      Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives
      shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section
      3 below.

   

  e. Governmental
        Review. The Buyer understands that no United States federal or state agency or any other government or governmental agency has passed
      upon or made any recommendation or endorsement of the Securities.

   

  f. Transfer
        or Re-sale. The Buyer understands that (i) the sale or resale of the Securities has not been and is not being registered under
      the 1933 Act or any applicable state securities laws, and the Securities may not be transferred unless (a) the Securities are sold
      pursuant to an effective registration statement under the 1933 Act, (b) the Buyer shall have delivered to the Company, at the cost
      of the Company, an opinion of counsel (which may be the Legal Counsel Opinion (as defined below)) that shall be in form, substance
      and scope customary for opinions of counsel in comparable transactions to the effect that the Securities to be sold or transferred
      may be sold or transferred pursuant to an exemption from such registration, which opinion shall be accepted by the Company, (c) the
      Securities are sold or transferred to an “affiliate” (as defined in Rule 144 promulgated under the 1933 Act (or a
      successor rule) (“Rule 144”)) of the Buyer who agrees to sell or otherwise transfer the Securities only in accordance
      with this Section 2(f) and who is an Accredited Investor, (d) the Securities are sold pursuant to Rule 144 or other applicable
      exemption, or (e) the Securities are sold pursuant to Regulation S under the 1933 Act (or a successor rule) (“Regulation
      S”), and the Buyer shall have delivered to the Company, at the cost of the Company, an opinion of counsel that shall be in
      form, substance and scope customary for opinions of counsel in corporate transactions, which opinion shall be accepted by the
      Company; (ii) any sale of such Securities made in reliance on Rule 144 may be made only in accordance with the terms of said Rule
      and further, if said Rule is not applicable, any re-sale of such Securities under circumstances in which the seller (or the person
      through whom the sale is made) may be deemed to be an underwriter (as that term is defined in the 1933 Act) may require compliance
      with some other exemption under the 1933 Act or the rules and regulations of the SEC thereunder; and (iii) neither the Company nor
      any other person is under any obligation to register such Securities under the 1933 Act or any state securities laws or to comply
      with the terms and conditions of any exemption thereunder (in each case). Notwithstanding the foregoing or anything else contained
      herein to the contrary, the Securities may be pledged in connection with a bona fide margin account or other lending
      arrangement secured by the Securities, and such pledge of Securities shall not be deemed to be a transfer, sale or assignment of the
      Securities hereunder, and the Buyer in effecting such pledge of Securities shall be not required to provide the Company with any
      notice thereof or otherwise make any delivery to the Company pursuant to this Agreement or otherwise.

   

  

  
  
    2

  

  
     

  

  
   

  g. Legends.
      The Buyer understands that until such time as the Note, Warrant, Conversion Shares, and/or Exercise Shares, have been registered
      under the 1933 Act or may be sold pursuant to Rule 144, Rule 144A under the 1933 Act, Regulation S, or other applicable exemption without
      any restriction as to the number of securities as of a particular date that can then be immediately sold, the Securities may bear a restrictive
      legend in substantially the following form (and a stop-transfer order may be placed against transfer of such Securities):

   

  “NEITHER
      THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE [CONVERTIBLE/EXERCISABLE]
      HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED
      FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE SECURITIES UNDER THE SECURITIES
      ACT OF 1933, AS AMENDED, OR (B) AN OPINION OF COUNSEL (WHICH COUNSEL SHALL BE SELECTED BY THE HOLDER), IN A GENERALLY ACCEPTABLE FORM,
      THAT REGISTRATION IS NOT REQUIRED UNDER SAID ACT OR (II) UNLESS SOLD PURSUANT TO RULE 144, RULE 144A, REGULATION S, OR OTHER APPLICABLE
      EXEMPTION UNDER SAID ACT. NOTWITHSTANDING THE FOREGOING, THE SECURITIES MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT
      OR OTHER LOAN OR FINANCING ARRANGEMENT SECURED BY THE SECURITIES.”

   

  The
      legend set forth above shall be removed and the Company shall issue a certificate or book entry statement for the applicable shares of
      Common Stock without such legend to the holder of any Security upon which it is stamped or (as requested by such holder) issue the applicable
      shares of Common Stock to such holder by electronic delivery by crediting the account of such holder’s broker with The Depository
      Trust Company (“DTC”), if, unless otherwise required by applicable state securities laws, (a) such Security is registered
      for sale under an effective registration statement filed under the 1933 Act or otherwise may be sold pursuant to Rule 144, Rule 144A,
      Regulation S, or other applicable exemption without any restriction as to the number of securities as of a particular date that can then
      be immediately sold, or (b) the Company or the Buyer provides the Legal Counsel Opinion (as contemplated by and in accordance with Section
      4(m) hereof) to the effect that a public sale or transfer of such Security may be made without registration under the 1933 Act, which
      opinion shall be accepted by the Company so that the sale or transfer is effected. The Company shall be responsible for the fees of its
      transfer agent and all DTC fees associated with any such issuance. The Buyer agrees to sell all Securities, including those represented
      by a certificate(s) from which the legend has been removed, in compliance with applicable prospectus delivery requirements, if any. In
      the event that the Company does not accept the opinion of counsel provided by the Buyer with respect to the transfer of Securities pursuant
      to an exemption from registration, such as Rule 144, Rule 144A, Regulation S, or other applicable exemption at the Deadline (as defined
      in the Note), it will be considered an Event of Default pursuant to Section 3.2 of the Note.

   

  

  
  
    3

  

  
     

  

  
   

  h. Authorization;
        Enforcement. This Agreement has been duly and validly authorized by the Buyer and has been duly executed and delivered on behalf
      of the Buyer, and this Agreement constitutes a valid and binding agreement of the Buyer enforceable in accordance with its terms,
      except as enforcement may be limited by bankruptcy, insolvency, reorganization, moratorium or other similar laws affecting
      creditors’ rights generally and except as may be limited by the exercise of judicial discretion in applying principles of
      equity.

   

  3. Representations
        and Warranties of the Company. The Company represents and warrants to the Buyer as of the Closing Date that:

   

  a. Organization
        and Qualification. The Company and each of its Subsidiaries (as defined below), if any, is a corporation duly organized, validly
      existing and in good standing under the laws of the jurisdiction in which it is incorporated, with full power and authority (corporate
      and other) to own, lease, use and operate its properties and to carry on its business as and where now owned, leased, used, operated
      and conducted. Schedule 3(a), if attached hereto, sets forth a list of all of the Subsidiaries of the Company and the jurisdiction in
      which each is incorporated. The Company and each of its Subsidiaries is duly qualified as a foreign corporation to do business and is
      in good standing in every jurisdiction in which its ownership or use of property or the nature of the business conducted by it makes
      such qualification necessary except where the failure to be so qualified or in good standing would not have a Material Adverse Effect.
      “Material Adverse Effect” means any material adverse effect on the business, operations, assets, financial condition or prospects
      of the Company or its Subsidiaries, if any, taken as a whole, or on the transactions contemplated hereby or by the agreements or instruments
      to be entered into in connection herewith. “Subsidiaries” means any corporation or other organization, whether incorporated
      or unincorporated, in which the Company owns, directly or indirectly, any equity or other ownership interest.

   

  b. Authorization;
        Enforcement. The Company has all requisite corporate power and authority to enter into and perform this Agreement, the Note, and
      to consummate the transactions contemplated hereby and thereby and to issue the Securities, in accordance with the terms hereof and thereof,
      (ii) the execution and delivery of this Agreement, the Warrant, the Note, Conversion Shares, and the Exercise Shares by the Company and
      the consummation by it of the transactions contemplated hereby and thereby (including without limitation, the issuance of the Note, Warrant,
      as well as the issuance and reservation for issuance of the Conversion Shares and Exercise Shares issuable upon conversion of the Note
      and/or exercise of the Warrant) have been duly authorized by the Company’s Board of Directors and no further consent or authorization
      of the Company, its Board of Directors, its shareholders, or its debt holders is required, (iii) this Agreement and the Note (together
      with any other instruments executed in connection herewith or therewith) have been duly executed and delivered by the Company by its
      authorized representative, and such authorized representative is the true and official representative with authority to sign this Agreement,
      the Note and the other instruments documents executed in connection herewith or therewith and bind the Company accordingly, and (iv)
      this Agreement constitutes, and upon execution and delivery by the Company of the Note, each of such instruments will constitute, a legal,
      valid and binding obligation of the Company, enforceable against the Company in accordance with their terms.

   

  c. Capitalization;
        Governing Documents. As of December 16, 2021, the authorized capital stock of the Company consists of: 500,000,000 authorized shares
      of Common Stock, of which 24,844,639 shares were issued and outstanding, and 10,000,001 authorized shares of preferred stock (consisting
      of 10,000,000 shares of Series A preferred stock and 1 share of Series B preferred stock), of which 5,000,001 shares were issued and
      outstanding (consisting of 5,000,000 shares of Series A preferred stock and 1 share of Series B preferred stock). All of such outstanding
      shares of capital stock of the Company, the Conversion Shares, and the Exercise Shares are, or upon issuance will be, duly authorized,
      validly issued, fully paid and non-assessable. No shares of capital stock of the Company are subject to preemptive rights or any other
      similar rights of the shareholders of the Company or any liens or encumbrances imposed through the actions or failure to act of the Company.
      As of the effective date of this Agreement, other than as publicly announced prior to such date and reflected in the SEC Documents of
      the Company (i) there are no outstanding options, warrants, scrip, rights to subscribe for, puts, calls, rights of first refusal, agreements,
      understandings, claims or other commitments or rights of any character whatsoever relating to, or securities or rights convertible into
      or exchangeable for any shares of capital stock of the Company or any of its Subsidiaries, or arrangements by which the Company or any
      of its Subsidiaries is or may become bound to issue additional shares of capital stock of the Company or any of its Subsidiaries, (ii)
      there are no agreements or arrangements under which the Company or any of its Subsidiaries is obligated to register the sale of any of
      its or their securities under the 1933 Act and (iii) there are no anti-dilution or price adjustment provisions contained in any security
      issued by the Company (or in any agreement providing rights to security holders) that will be triggered by the issuance of any of the
      Securities. The Company has furnished to the Buyer true and correct copies of the Company’s Certificate of Incorporation as in
      effect on the date hereof (“Certificate of Incorporation”), the Company’s By-laws, as in effect on the date hereof
      (the “By-laws”), and the terms of all securities convertible into or exercisable for Common Stock of the Company and the
      material rights of the holders thereof in respect thereto.

   

  

  
  
    4

  

  
     

  

  
   

  d. Issuance
        of Conversion Shares and Exercise Shares. The Conversion Shares and Exercise Shares are duly authorized and reserved for issuance
      and, upon conversion of the Note and/or exercise of the Warrant in accordance with its terms, will be validly issued, fully paid and
      non-assessable, and free from all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to
      preemptive rights or other similar rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

   

  e. Issuance
        of Warrant. The issuance of the Warrant is duly authorized and will be validly issued, fully paid and non-assessable, and free from
      all taxes, liens, claims and encumbrances with respect to the issue thereof and shall not be subject to preemptive rights or other similar
      rights of shareholders of the Company and will not impose personal liability upon the holder thereof.

   

  f. Acknowledgment
        of Dilution. The Company understands and acknowledges the potentially dilutive effect of the Conversion Shares and Exercise Shares
      to the Common Stock upon the conversion of the Note and/or exercise of the Warrant. The Company further acknowledges that its obligation
      to issue, upon conversion of the Note and/or exercise of the Warrant, the Conversion Shares and/or Exercise Shares, are absolute and
      unconditional regardless of the dilutive effect that such issuance may have on the ownership interests of other shareholders of the Company.

   

  g. No
        Conflicts. The execution, delivery and performance of this Agreement and the Note by the Company and the consummation by the Company
      of the transactions contemplated hereby and thereby (including, without limitation, the issuance and reservation for issuance of the
      Conversion Shares and Exercise Shares) will not (i) conflict with or result in a violation of any provision of the Certificate of Incorporation
      or By-laws, or (ii) violate or conflict with, or result in a breach of any provision of, or constitute a default (or an event which with
      notice or lapse of time or both could become a default) under, or give to others any rights of termination, amendment, acceleration or
      cancellation of, any agreement, note, evidence of indebtedness, indenture, patent, patent license or instrument to which the Company
      or any of its Subsidiaries is a party, or (iii) result in a violation of any law, rule, regulation, order, judgment or decree (including
      federal and state securities laws and regulations and regulations of any self-regulatory organizations to which the Company or its securities
      is subject) applicable to the Company or any of its Subsidiaries or by which any property or asset of the Company or any of its Subsidiaries
      is bound or affected (except for such conflicts, defaults, terminations, amendments, accelerations, cancellations and violations as would
      not, individually or in the aggregate, have a Material Adverse Effect), or (iv) trigger any anti-dilution and/or ratchet provision contained
      in any other contract in which the Company is a party thereto or any security issued by the Company. Neither the Company nor any of its
      Subsidiaries is in violation of its Certificate of Incorporation, By-laws or other organizational documents and neither the Company nor
      any of its Subsidiaries is in default (and no event has occurred which with notice or lapse of time or both could put the Company or
      any of its Subsidiaries in default) under, and neither the Company nor any of its Subsidiaries has taken any action or failed to take
      any action that would give to others any rights of termination, amendment, acceleration or cancellation of, any agreement, indenture
      or instrument to which the Company or any of its Subsidiaries is a party or by which any property or assets of the Company or any of
      its Subsidiaries is bound or affected, except for possible defaults as would not, individually or in the aggregate, have a Material Adverse
      Effect. The businesses of the Company and its Subsidiaries, if any, are not being conducted, and shall not be conducted so long as the
      Buyer owns any of the Securities, in violation of any law, ordinance or regulation of any governmental entity. Except as specifically
      contemplated by this Agreement and as required under the 1933 Act and any applicable state securities laws, the Company is not required
      to obtain any consent, authorization or order of, or make any filing or registration with, any court, governmental agency, regulatory
      agency, self-regulatory organization or stock market or any third party in order for it to execute, deliver or perform any of its obligations
      under this Agreement and the Note in accordance with the terms hereof or thereof or to issue and sell the Note in accordance with the
      terms hereof and, upon conversion of the Note and/or exercise of the Warrant, issue Conversion Shares and/or Exercise Shares as applicable.
      All consents, authorizations, orders, filings and registrations which the Company is required to obtain pursuant to the preceding sentence
      have been obtained or effected on or prior to the date hereof. The Company is not in violation of the listing requirements of the Principal
      Market (as defined herein) and does not reasonably anticipate that the Common Stock will be delisted by the Principal Market in the foreseeable
      future. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing. The
      “Principal Market” shall mean the principal securities exchange or trading market where such Common Stock is listed or traded,
      including but not limited to any tier of the OTC Markets, any tier of the NASDAQ Stock Market (including NASDAQ Capital Market), or the
      NYSE American, or any successor to such markets.

   

  

  
  
    5

  

  
     

  

  
   

  h. SEC
        Documents; Financial Statements. The Company has filed all reports, schedules, forms, statements and other documents required to
      be filed by it with the SEC pursuant to the reporting requirements of the Securities Exchange Act of 1934, as amended (the “1934
      Act”) (all of the foregoing filed prior to the date hereof and all exhibits included therein and financial statements and schedules
      thereto and documents (other than exhibits to such documents) incorporated by reference therein, being hereinafter referred to herein
      as the “SEC Documents”). As of their respective dates, the SEC Documents complied in all material respects with the requirements
      of the 1934 Act and the rules and regulations of the SEC promulgated thereunder applicable to the SEC Documents, and none of the SEC
      Documents, at the time they were filed with the SEC, contained any untrue statement of a material fact or omitted to state a material
      fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which they
      were made, not misleading. None of the statements made in any such SEC Documents is, or has been, required to be amended or updated under
      applicable law (except for such statements as have been amended or updated in subsequent filings prior the date hereof). As of their
      respective dates, the financial statements of the Company included in the SEC Documents complied as to form in all material respects
      with applicable accounting requirements and the published rules and regulations of the SEC with respect thereto. Such financial statements
      have been prepared in accordance with United States generally accepted accounting principles, consistently applied, during the periods
      involved and fairly present in all material respects the consolidated financial position of the Company and its consolidated Subsidiaries
      as of the dates thereof and the consolidated results of their operations and cash flows for the periods then ended (subject, in the case
      of unaudited statements, to normal year-end audit adjustments). Except as set forth in the financial statements of the Company included
      in the SEC Documents, the Company has no liabilities, contingent or otherwise, other than (i) liabilities incurred in the ordinary course
      of business subsequent to September 30, 2021, and (ii) obligations under contracts and commitments incurred in the ordinary course of
      business and not required under generally accepted accounting principles to be reflected in such financial statements, which, individually
      or in the aggregate, are not material to the financial condition or operating results of the Company. The Company is subject to the reporting
      requirements of the 1934 Act. The Company has not been a “shell company” as described in Rule 144(i)(1)(i) since October
      1, 2020.

   

  i. Absence
        of Certain Changes. Since September 30, 2021, there has been no material adverse change and no material adverse development in the
      assets, liabilities, business, properties, operations, financial condition, results of operations, prospects or 1934 Act reporting status
      of the Company or any of its Subsidiaries.

   

  j. Absence
        of Litigation. There is no action, suit, claim, proceeding, inquiry or investigation before or by any court, public board, government
      agency, self-regulatory organization or body pending or, to the knowledge of the Company or any of its Subsidiaries, threatened against
      or affecting the Company or any of its Subsidiaries, or their officers or directors in their capacity as such, that could have a Material
      Adverse Effect. The SEC Documents contain a complete list and summary description of any pending or, to the knowledge of the Company,
      threatened proceeding against or affecting the Company or any of its Subsidiaries, without regard to whether it would have a Material
      Adverse Effect. The Company and its Subsidiaries are unaware of any facts or circumstances which might give rise to any of the foregoing.

   

  k. Intellectual
        Property. The Company and each of its Subsidiaries owns or possesses the requisite licenses or rights to use all patents, patent
      applications, patent rights, inventions, know-how, trade secrets, trademarks, trademark applications, service marks, service names, trade
      names and copyrights (“Intellectual Property”) necessary to enable it to conduct its business as now operated (and, as presently
      contemplated to be operated in the future); there is no claim or action by any person pertaining to, or proceeding pending, or to the
      Company’s knowledge threatened, which challenges the right of the Company or of a Subsidiary with respect to any Intellectual Property
      necessary to enable it to conduct its business as now operated (and, as presently contemplated to be operated in the future); to the
      best of the Company’s knowledge, the Company’s or its Subsidiaries’ current and intended products, services and processes
      do not infringe on any Intellectual Property or other rights held by any person; and the Company is unaware of any facts or circumstances
      which might give rise to any of the foregoing. The Company and each of its Subsidiaries have taken reasonable security measures to protect
      the secrecy, confidentiality and value of their Intellectual Property.

   

  

  
  
    6

  

  
     

  

  
   

  l. No
        Materially Adverse Contracts, Etc. Neither the Company nor any of its Subsidiaries is subject to any charter, corporate or other
      legal restriction, or any judgment, decree, order, rule or regulation which in the judgment of the Company’s officers has or is
      expected in the future to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries is a party to any contract
      or agreement which in the judgment of the Company’s officers has or is expected to have a Material Adverse Effect.

   

  m. Tax
        Status. The Company and each of its Subsidiaries has made or filed all federal, state and foreign income and all other tax returns,
      reports and declarations required by any jurisdiction to which it is subject (unless and only to the extent that the Company and each
      of its Subsidiaries has set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) and
      has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
      returns, reports and declarations, except those being contested in good faith and has set aside on its books provisions reasonably adequate
      for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no
      unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company know
      of no basis for any such claim. The Company has not executed a waiver with respect to the statute of limitations relating to the assessment
      or collection of any foreign, federal, state or local tax. None of the Company’s tax returns is presently being audited by any
      taxing authority.

   

  n. Transactions
        with Affiliates. Except for arm’s length transactions pursuant to which the Company or any of its Subsidiaries makes payments
      in the ordinary course of business upon terms no less favorable than the Company or any of its Subsidiaries could obtain from third parties
      and other than the grant of stock options described in the SEC Documents, none of the officers, directors, or employees of the Company
      is presently a party to any transaction with the Company or any of its Subsidiaries (other than for services as employees, officers and
      directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental
      of real or personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the
      knowledge of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has
      a substantial interest or is an officer, director, trustee or partner.

   

  o. Disclosure.
      All information relating to or concerning the Company or any of its Subsidiaries set forth in this Agreement and provided to the
      Buyer pursuant to Section 2(d) hereof and otherwise in connection with the transactions contemplated hereby is true and correct in all
      material respects and the Company has not omitted to state any material fact necessary in order to make the statements made herein or
      therein, in light of the circumstances under which they were made, not misleading. No event or circumstance has occurred or exists with
      respect to the Company or any of its Subsidiaries or its or their business, properties, prospects, operations or financial conditions,
      which, under applicable law, rule or regulation, requires public disclosure or announcement by the Company but which has not been so
      publicly announced or disclosed (assuming for this purpose that the Company’s reports filed under the 1934 Act are being incorporated
      into an effective registration statement filed by the Company under the 1933 Act).

   

  p. Acknowledgment
        Regarding Buyer’s Purchase of Securities. The Company acknowledges and agrees that the Buyer is acting solely in the capacity
      of arm’s length purchaser with respect to this Agreement and the transactions contemplated hereby. The Company further acknowledges
      that the Buyer is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to this Agreement
      and the transactions contemplated hereby and any statement made by the Buyer or any of its respective representatives or agents in connection
      with this Agreement and the transactions contemplated hereby is not advice or a recommendation and is merely incidental to the Buyer’s
      purchase of the Securities. The Company further represents to the Buyer that the Company’s decision to enter into this Agreement
      has been based solely on the independent evaluation of the Company and its representatives.

   

  q. No
        Integrated Offering. Neither the Company, nor any of its affiliates, nor any person acting on its or their behalf, has directly
      or indirectly made any offers or sales in any security or solicited any offers to buy any security under circumstances that would
      require registration under the 1933 Act of the issuance of the Securities to the Buyer. The issuance of the Securities to the Buyer
      will not be integrated with any other issuance of the Company’s securities (past, current or future) for purposes of any
      shareholder approval provisions applicable to the Company or its securities.

   

  

  
  
    7

  

  
     

  

  
   

  r. No
        Brokers; No Solicitation. Except with respect to Carter, Terry, & Company, Inc., a registered broker-dealer (CRD#: 16365), the
      Company has taken no action which would give rise to any claim by any person for brokerage commissions, transaction fees or similar payments
      relating to this Agreement or the transactions contemplated hereby. The Company acknowledges and agrees that neither the Buyer nor its
      employee(s), member(s), beneficial owner(s), or partner(s) solicited the Company to enter into this Agreement and consummate the transactions
      described in this Agreement.

   

  s. Permits;
        Compliance. The Company and each of its Subsidiaries is in possession of all franchises, grants, authorizations, licenses, permits,
      easements, variances, exemptions, consents, certificates, approvals and orders necessary to own, lease and operate its properties and
      to carry on its business as it is now being conducted (collectively, the “Company Permits”), and there is no action pending
      or, to the knowledge of the Company, threatened regarding suspension or cancellation of any of the Company Permits. Neither the Company
      nor any of its Subsidiaries is in conflict with, or in default or violation of, any of the Company Permits, except for any such conflicts,
      defaults or violations which, individually or in the aggregate, would not reasonably be expected to have a Material Adverse Effect. Since
      September 30, 2021, neither the Company nor any of its Subsidiaries has received any notification with respect to possible conflicts,
      defaults or violations of applicable laws, except for notices relating to possible conflicts, defaults or violations, which conflicts,
      defaults or violations would not have a Material Adverse Effect.

   

  t. Environmental
        Matters.

   

  (i) There
      are, to the Company’s knowledge, with respect to the Company or any of its Subsidiaries or any predecessor of the Company, no past
      or present violations of Environmental Laws (as defined below), releases of any material into the environment, actions, activities, circumstances,
      conditions, events, incidents, or contractual obligations which may give rise to any common law environmental liability or any liability
      under the Comprehensive Environmental Response, Compensation and Liability Act of 1980 or similar federal, state, local or foreign laws
      and neither the Company nor any of its Subsidiaries has received any notice with respect to any of the foregoing, nor is any action pending
      or, to the Company’s knowledge, threatened in connection with any of the foregoing. The term “Environmental Laws” means
      all federal, state, local or foreign laws relating to pollution or protection of human health or the environment (including, without
      limitation, ambient air, surface water, groundwater, land surface or subsurface strata), including, without limitation, laws relating
      to emissions, discharges, releases or threatened releases of chemicals, pollutants contaminants, or toxic or hazardous substances or
      wastes (collectively, “Hazardous Materials”) into the environment, or otherwise relating to the manufacture, processing,
      distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes,
      decrees, demands or demand letters, injunctions, judgments, licenses, notices or notice letters, orders, permits, plans or regulations
      issued, entered, promulgated or approved thereunder.

   

  (ii) Other
      than those that are or were stored, used or disposed of in compliance with applicable law, no Hazardous Materials are contained on or
      about any real property currently owned, leased or used by the Company or any of its Subsidiaries, and no Hazardous Materials were released
      on or about any real property previously owned, leased or used by the Company or any of its Subsidiaries during the period the property
      was owned, leased or used by the Company or any of its Subsidiaries, except in the normal course of the Company’s or any of its
      Subsidiaries’ business.

   

  (iii) There
      are no underground storage tanks on or under any real property owned, leased or used by the Company or any of its Subsidiaries that are
      not in compliance with applicable law.

   

  u. Title
        to Property. The Company and its Subsidiaries have good and marketable title in fee simple to all real property and good and
      marketable title to all personal property owned by them which is material to the business of the Company and its Subsidiaries, in
      each case free and clear of all liens, encumbrances and defects except such as are described in Schedule 3(u), if attached hereto,
      or such as would not have a Material Adverse Effect. Any real property and facilities held under lease by the Company and its
      Subsidiaries are held by them under valid, subsisting and enforceable leases with such exceptions as would not have a Material
      Adverse Effect.

   

  

  
  
    8

  

  
     

  

  
   

  v. Insurance.
      The Company and each of its Subsidiaries are insured by insurers of recognized financial responsibility against such losses and risks
      and in such amounts as management of the Company believes to be prudent and customary in the businesses in which the Company and its
      Subsidiaries are engaged. Neither the Company nor any such Subsidiary has any reason to believe that it will not be able to renew its
      existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary
      to continue its business at a cost that would not have a Material Adverse Effect. Upon written request the Company will provide to the
      Buyer true and correct copies of all policies relating to directors’ and officers’ liability coverage, errors and omissions
      coverage, and commercial general liability coverage.

   

  w. Internal
        Accounting Controls. The Company and each of its Subsidiaries maintain a system of internal accounting controls sufficient, in the
      judgment of the Company’s board of directors, to provide reasonable assurance that (i) transactions are executed in accordance
      with management’s general or specific authorizations, (ii) transactions are recorded as necessary to permit preparation of financial
      statements in conformity with generally accepted accounting principles and to maintain asset accountability, (iii) access to assets is
      permitted only in accordance with management’s general or specific authorization and (iv) the recorded accountability for assets
      is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences.

   

  x. Foreign
        Corrupt Practices. Neither the Company, nor any of its Subsidiaries, nor any director, officer, agent, employee or other person acting
      on behalf of the Company or any Subsidiary has, in the course of his actions for, or on behalf of, the Company, used any corporate funds
      for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; made any direct or indirect
      unlawful payment to any foreign or domestic government official or employee from corporate funds; violated or is in violation of any
      provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or made any bribe, rebate, payoff, influence payment, kickback
      or other unlawful payment to any foreign or domestic government official or employee.

   

  y. Solvency.
      The Company (after giving effect to the transactions contemplated by this Agreement) is solvent (i.e., its assets have a fair
      market value in excess of the amount required to pay its probable liabilities on its existing debts as they become absolute and matured)
      and currently the Company has no information that would lead it to reasonably conclude that the Company would not, after giving effect
      to the transaction contemplated by this Agreement, have the ability to, nor does it intend to take any action that would impair its ability
      to, pay its debts from time to time incurred in connection therewith as such debts mature. The Company’s financial statements for
      its most recent fiscal year end and interim financial statements have been prepared assuming the Company will continue as a going concern,
      which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.

   

  z. No
        Investment Company. The Company is not, and upon the issuance and sale of the Securities as contemplated by this Agreement will not
      be an “investment company” required to be registered under the Investment Company Act of 1940 (an “Investment Company”).
      The Company is not controlled by an Investment Company.

   

  aa.
      No Off Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company or any of its
      Subsidiaries and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in its 1934 Act
      filings and is not so disclosed or that otherwise could be reasonably likely to have a Material Adverse Effect.

   

  bb. No
        Disqualification Events. None of the Company, any of its predecessors, any affiliated issuer, any director, executive officer,
      other officer of the Company participating in the offering hereunder, any beneficial owner of 20% or more of the Company’s
      outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405
      under the 1933 Act) connected with the Company in any capacity at the time of sale (each, an “Issuer Covered Person”) is
      subject to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the 1933 Act (a
      “Disqualification Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has
      exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event.

   

  

  
  
    9

  

  
     

  

  
   

  cc.
      Manipulation of Price. The Company has not, and to its knowledge no one acting on its behalf has: (i) taken, directly or indirectly,
      any action designed to cause or to result, or that could reasonably be expected to cause or result, in the stabilization or manipulation
      of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased,
      or paid any compensation for soliciting purchases of, any of the Securities, or (iii) paid or agreed to pay to any person any compensation
      for soliciting another to purchase any other securities of the Company.

   

  dd.
      Bank Holding Company Act. Neither the Company nor any of its Subsidiaries is subject to the Bank Holding Company Act of 1956,
      as amended (the “BHCA”) and to regulation by the Board of Governors of the Federal Reserve System (the “Federal Reserve”).
      Neither the Company nor any of its Subsidiaries or affiliates owns or controls, directly or indirectly, five percent (5%) or more of
      the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity
      that is subject to the BHCA and to regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or affiliates exercises
      a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the
      Federal Reserve.

   

  ee.
      Illegal or Unauthorized Payments; Political Contributions. Neither the Company nor any of its Subsidiaries nor, to the Company’s
      knowledge, any of the officers, directors, employees, agents or other representatives of the Company or any of its Subsidiaries or any
      other business entity or enterprise with which the Company or any Subsidiary is or has been affiliated or associated, has, directly or
      indirectly, made or authorized any payment, contribution or gift of money, property, or services, whether or not in contravention of
      applicable law, (i) as a kickback or bribe to any person or (ii) to any political organization, or the holder of or any aspirant to any
      elective or appointive public office except for personal political contributions not involving the direct or indirect use of funds of
      the Company or any of its Subsidiaries.

   

  ff.
      Breach of Representations and Warranties by the Company. The Company agrees that if the Company breaches any of the representations
      or warranties set forth in this Section 3 and in addition to any other remedies available to the Buyer pursuant to this Agreement, it
      will be considered an Event of Default under Section 3.4 of the Note.

   

  4. ADDITIONAL
        COVENANTS, AGREEMENTS AND ACKNOWLEDGEMENTS.

   

  a. Best
        Efforts. The parties shall use their best efforts to satisfy timely each of the conditions described in Section 6 and 7 of this Agreement.

   

  b. Form
        D; Blue Sky Laws. The Company agrees to file a Form D with respect to the Securities if required under Regulation D and to provide
      a copy thereof to the Buyer promptly after such filing. The Company shall, on or before the Closing Date, take such action as the Company
      shall reasonably determine is necessary to qualify the Securities for sale to the Buyer at the applicable closing pursuant to this Agreement
      under applicable securities or “blue sky” laws of the states of the United States (or to obtain an exemption from such qualification),
      and shall provide evidence of any such action so taken to the Buyer on or prior to the Closing Date.

   

  c. Use
        of Proceeds. The Company shall use the proceeds for business development, and not for (i) the repayment of any indebtedness owed
      to officers, directors or employees of the Company or their affiliates, (ii) the repayment of any debt issued in corporate finance transactions,
      (iii) any loan to or investment in any other corporation, partnership, enterprise or other person (except in connection with the Company’s
      currently existing operations), (iv) any loan, credit, or advance to any officers, directors, employees, or affiliates of the Company,
      or (v) in violation or contravention of any applicable law, rule or regulation.

   

  

  
  
    10

  

  
     

  

  
   

  d.
        Right of Participation and First Refusal.

   

  (i) Other
        than arrangements that are in place or disclosed in SEC Documents prior to the date of this
        Agreement, from the date of this Agreement until the Note is extinguished in its entirety, the Company will not, (i) directly or indirectly,
        offer, sell, grant any option to purchase, or otherwise dispose of (or announce any offer, sale, grant or any option to purchase or other
        disposition of) any of its or its Subsidiaries’ debt, equity, or equity equivalent securities, including without limitation any
        debt, preferred shares or other instrument or security that is, at any time during its life and/or under any circumstances, convertible
        into, exchangeable, or exercisable for Common Stock (any such offer, sale, grant, disposition or announcement being referred to as a
        “Subsequent Placement”) or (ii) enter into any definitive agreement with regard to the foregoing, in each case unless the
        Company shall have first complied with this Section 4(d).

   

  (ii) The
        Company shall deliver to the Buyer an irrevocable written notice (the “Offer Notice”) of any proposed or intended Subsequent
        Placement, which shall (w) identify and describe the Subsequent Placement, (x) describe the price and other terms upon which they are
        to be issued, sold or exchanged, and the number or amount of the securities in the Subsequent Placement to be issued, sold, or exchanged
        and (y) offer to issue and sell to or exchange with the Buyer at least one hundred percent (100%) of the securities in the Subsequent
        Placement (in each case, an “Offer”).

   

  (iii) To
        accept an Offer, in whole or in part, the Buyer must deliver a written notice (the “Notice of Acceptance”) to the Company
        prior to the end of the fifth (5th) Trading Day (as defined in the Note) after the Buyer’s receipt of the Offer Notice
        (the “Offer Period”), setting forth the amount that the Buyer elects to purchase (the “Subscription Amount”).
        The Company shall complete the Subsequent Placement and issue and sell the Subscription Amount to the Buyer upon terms and conditions
        (including, without limitation, unit prices and interest rates) set forth in the Offer Notice, unless a change to such terms and conditions
        is agreed to in writing between the Company and Buyer.

   

  (iv) Notwithstanding
        anything to the contrary contained herein, if the Company desires to modify or amend the terms or conditions of a Subsequent Placement
        at any time after the Offer Notice is given to Buyer (provided, however, that such modification or amendment to the terms or conditions
        cannot occur during any Offer Period), the Company shall deliver to the Buyer a new Offer Notice and the Offer Period of such new Offer
        shall expire at the end of the fifth (5th) Trading Day after the Buyer’s receipt of such new Offer Notice.

   

  (v) Notwithstanding
      the foregoing, this Section 4(d) of this Agreement shall not apply to issuances of Common Stock that have been registered by the Company
      in its registration statement filed on May 17, 2021; effective September 27, 2021.

   

  e. Usury.
      To the extent it may lawfully do so, the Company hereby agrees not to insist upon or plead or in any manner whatsoever claim, and will
      resist any and all efforts to be compelled to take the benefit or advantage of, usury laws wherever enacted, now or at any time hereafter
      in force, in connection with any action or proceeding that may be brought by the Buyer in order to enforce any right or remedy under
      this Agreement, the Note and any document, agreement or instrument contemplated thereby. Notwithstanding any provision to the contrary
      contained in this Agreement, the Note and any document, agreement or instrument contemplated thereby, it is expressly agreed and provided
      that the total liability of the Company under this Agreement, the Note or any document, agreement or instrument contemplated thereby
      for payments which under applicable law are in the nature of interest shall not exceed the maximum lawful rate authorized under applicable
      law (the “Maximum Rate”), and, without limiting the foregoing, in no event shall any rate of interest or default interest,
      or both of them, when aggregated with any other sums which under applicable law in the nature of interest that the Company may be obligated
      to pay under this Agreement, the Note and any document, agreement or instrument contemplated thereby exceed such Maximum Rate. It is
      agreed that if the maximum contract rate of interest allowed by law applicable to this Agreement, the Note and any document, agreement
      or instrument contemplated thereby is increased or decreased by statute or any official governmental action subsequent to the date hereof,
      the new maximum contract rate of interest allowed by law will be the Maximum Rate applicable to this Agreement, the Note and any document,
      agreement or instrument contemplated thereby from the effective date thereof forward, unless such application is precluded by applicable
      law. If under any circumstances whatsoever, interest in excess of the Maximum Rate is paid by the Company to the Buyer with respect to
      indebtedness evidenced by this Agreement, the Note and any document, agreement or instrument contemplated thereby, such excess shall
      be applied by the Buyer to the unpaid principal balance of any such indebtedness or be refunded to the Company, the manner of handling
      such excess to be at the Buyer’s election.

   

  f. Restriction
        on Activities. Commencing as of the date first above written, and until the earlier of payment of the Note in full or full conversion
      of the Note, the Company shall not, directly or indirectly, without the Buyer’s prior written consent, which consent shall not
      be unreasonably withheld: (a) change the nature of its business; or (b) sell, divest, acquire, change the structure of any material assets
      other than in the ordinary course of business.

   

  

  
  
    11

  

  
     

  

  
   

  g. Listing.
      The Company will, so long as the Buyer owns any of the Securities, maintain the listing and trading of its Common Stock on the Principal
      Market or any equivalent replacement exchange or electronic quotation system (including but not limited to the Pink Sheets electronic
      quotation system) and will comply in all respects with the Company’s reporting, filing and other obligations under the bylaws or
      rules of the Financial Industry Regulatory Authority (“FINRA”) and such exchanges, as applicable. The Company shall promptly
      provide to the Buyer copies of any notices it receives from the Principal Market and any other exchanges or electronic quotation systems
      on which the Common Stock is then traded regarding the continued eligibility of the Common Stock for listing on such exchanges and quotation
      systems.

   

  h. Corporate
        Existence. The Company will, so long as the Buyer beneficially owns any of the Securities, maintain its corporate existence and shall
      not sell all or substantially all of the Company’s assets, except in the event of a merger or consolidation or sale of all or substantially
      all of the Company’s assets, where the surviving or successor entity in such transaction (i) assumes the Company’s obligations
      hereunder and under the agreements and instruments entered into in connection herewith and (ii) is a publicly traded corporation whose
      Common Stock is listed for trading or quotation on the Principal Market, any tier of the NASDAQ Stock Market, the New York Stock Exchange
      or the NYSE MKT.

   

  i. No
        Integration. The Company shall not make any offers or sales of any security (other than the Securities) under circumstances that
      would require registration of the Securities being offered or sold hereunder under the 1933 Act or cause the offering of the Securities
      to be integrated with any other offering of securities by the Company for the purpose of any stockholder approval provision applicable
      to the Company or its securities.

   

  j. Breach
        of Covenants. The Company acknowledges and agrees that if the Company breaches any of the covenants set forth in this Section 4,
      in addition to any other remedies available to the Buyer pursuant to this Agreement, it will be considered an Event of Default under
      Section 3.3 of the Note.

   

  k. Compliance
        with 1934 Act; Public Information Failures. For so long as the Buyer beneficially owns the Note or Conversion Shares, the Company
      shall comply with the reporting requirements of the 1934 Act; and the Company shall continue to be subject to the reporting requirements
      of the 1934 Act.

   

  l. Acknowledgement
        Regarding Buyer’s Trading Activity. Until the Note is fully repaid or fully converted, the Buyer shall not effect any “short
      sale” (as such term is defined in Rule 200 of Regulation SHO of the 1934 Act) of the Common Stock which establishes a net short
      position with respect to the Common Stock.

   

  m. [Intentionally
      Omitted].

   

  n. Legal
        Counsel Opinions. Upon the request of the Buyer from to time to time, the Company shall be responsible (at its cost) for promptly
      supplying to the Company’s transfer agent and the Buyer a customary legal opinion letter of its counsel (the “Legal Counsel
      Opinion”) to the effect that the resale of the Conversion Shares and/or Exercise Shares by the Buyer or its affiliates, successors
      and assigns is exempt from the registration requirements of the 1933 Act pursuant to Rule 144 (provided the requirements of Rule 144
      are satisfied and provided the Conversion Shares and/or Exercise Shares are not then registered under the 1933 Act for resale pursuant
      to an effective registration statement) or other applicable exemption (provided the requirements of such other applicable exemption are
      satisfied). In addition, the Buyer may (at the Company’s cost) at any time secure its own legal counsel to issue the Legal Counsel
      Opinion, and the Company will instruct its transfer agent to accept such opinion. The Company hereby agrees that it may never take the
      position that it is a “shell company” in connection with its obligations under this Agreement or otherwise.

   

  o. Registration
        Rights. The Company hereby grants to the Buyer the piggy-back registration rights set forth on Exhibit B hereto and registration
      rights set forth in the registration rights agreement attached hereto as Exhibit C (the “RRA”).

   

  

  
  
    12

  

  
     

  

  
   

  p. Most
        Favored Nation. While the Note or any principal amount, interest or fees or expenses due thereunder remain outstanding and unpaid,
      the Company shall not enter into any public or private offering of its securities (including securities convertible into shares of Common
      Stock) with any individual or entity (an “Other Investor”) that has the effect of establishing rights or otherwise benefiting
      such Other Investor in a manner more favorable in any material respect to such Other Investor than the rights and benefits established
      in favor of the Buyer by this Agreement or the Note unless, in any such case, the Buyer has been provided with such rights and benefits
      pursuant to a definitive written agreement or agreements between the Company and the Buyer.

   

  q. Subsequent
        Variable Rate Transactions. From the date hereof until such time as the Note is fully converted or fully repaid, the Company shall
      be prohibited from effecting or entering into an agreement involving a Variable Rate Transaction. “Variable Rate Transaction”
      means a transaction in which the Company (i) issues or sells any debt or equity securities that are convertible into, exchangeable or
      exercisable for, or include the right to receive, additional shares of Common Stock either (A) at a conversion price, exercise price
      or exchange rate or other price that is based upon, and/or varies with, the trading prices of or quotations for the shares of Common
      Stock at any time after the initial issuance of such debt or equity securities or (B) with a conversion, exercise or exchange price that
      is subject to being reset at some future date after the initial issuance of such debt or equity security or upon the occurrence of specified
      or contingent events directly or indirectly related to the business of the Company or the market for the Common Stock or (ii) enters
      into any agreement, including, but not limited to, an equity line of credit, whereby the Company may issue securities at a future determined
      price. The Buyer shall be entitled to obtain injunctive relief against the Company to preclude any such issuance, which remedy shall
      be in addition to any right to collect damages.

   

  r. [Intentionally
        Omitted].

   

  s. Non-Public
        Information. The Company covenants and agrees that neither it, nor any other person acting on its behalf will provide the Buyer or
      its agents or counsel with any information that constitutes, or the Company reasonably believes constitutes, material non-public information,
      unless prior thereto the Buyer shall have consented to the receipt of such information and agreed with the Company to keep such information
      confidential. The Company understands and confirms that the Buyer shall be relying on the foregoing covenant in effecting transactions
      in securities of the Company. To the extent that the Company delivers any material, non-public information to the Buyer without such
      Buyer’s consent, the Company hereby covenants and agrees that such Buyer shall not have any duty of confidentiality to the Company,
      any of its Subsidiaries, or any of their respective officers, directors, agents, employees or affiliates, not to trade on the basis of,
      such material, non- public information, provided that the Buyer shall remain subject to applicable law. To the extent that any notice
      provided, information provided, or any other communications made by the Company, to the Buyer, constitutes or contains material non-public
      information regarding the Company or any Subsidiaries, the Company shall simultaneously file such notice or other material information
      with the SEC pursuant to a Current Report on Form 8-K. In addition to any other remedies provided by this Agreement or the related transaction
      documents, if the Company provides any material non-public information to the Buyer without their prior written consent, and it fails
      to immediately (no later than that business day) file a Form 8-K disclosing this material non-public information, it shall pay the Buyer
      as partial liquidated damages and not as a penalty a sum equal to $3,000 per day beginning with the day the information is disclosed
      to the Buyer and ending and including the day the Form 8-K disclosing this information is filed.

   

  t. D&O
        Insurance. Within 60 calendar days of the Closing, the Company shall purchase director and officer insurance on behalf of the Company’s
      (including its subsidiary) officers and directors for a period of 18 months after the Closing with respect to any losses, claims, damages,
      liabilities, costs and expense in connection with any actual or threatened claim or proceeding that is based on, or arises out of their
      status as a director or officer of the Company. The insurance policy shall provide for two years of tail coverage.

   

  

  
  
    13

  

  
     

  

  
   

  5. Transfer
        Agent Instructions. The Company shall issue irrevocable instructions to the Company’s transfer agent to issue certificates
      and/or issue shares electronically at the Buyer’s option, registered in the name of the Buyer or its nominee, upon conversion of
      the Note and/or exercise of the Warrant, the Conversion Shares and Exercise Shares, in such amounts as specified from time to time by
      the Buyer to the Company in accordance with the terms thereof (the “Irrevocable Transfer Agent Instructions”). In the event
      that the Company proposes to replace its transfer agent, the Company shall provide, prior to the effective date of such replacement,
      a fully executed Irrevocable Transfer Agent Instructions in a form as initially delivered pursuant to this Agreement (including but not
      limited to the provision to irrevocably reserved shares of Common Stock in the Reserved Amount (as defined in the Note)) signed by the
      successor transfer agent to the Company and the Company. Prior to registration of the Conversion Shares and/or Exercise Shares under
      the 1933 Act or the date on which the Conversion Shares and/or Exercise Shares may be sold pursuant to Rule 144, Rule 144A, Regulation
      S, or other applicable exemption without any restriction as to the number of Securities as of a particular date that can then be immediately
      sold, all such certificates or book entry shares shall bear the restrictive legend specified in Section 2(g) of this Agreement. The Company
      warrants that: (i) no instruction other than the Irrevocable Transfer Agent Instructions referred to in this Section 5 will be given
      by the Company to its transfer agent and that the Securities shall otherwise be freely transferable on the books and records of the Company
      as and to the extent provided in this Agreement and the Note; (ii) it will not direct its transfer agent not to transfer or delay, impair,
      and/or hinder its transfer agent in transferring (or issuing)(electronically or in certificated form) any certificate for Securities
      to be issued to the Buyer upon conversion of or otherwise pursuant to the Note and/or upon exercise of or otherwise pursuant to the Warrant
      as and when required by the Note and this Agreement; (iii) it will not fail to remove (or directs its transfer agent not to remove or
      impairs, delays, and/or hinders its transfer agent from removing) any restrictive legend (or to withdraw any stop transfer instructions
      in respect thereof) on any certificate for any Securities issued to the Buyer upon conversion of or otherwise pursuant to the Note and/or
      upon exercise of or otherwise pursuant to the Warrant as and when required by the Note, Warrant, and/or this Agreement and (iv) it will
      provide any required corporate resolutions and issuance approvals to its transfer agent within 6 hours of each conversion of the Note
      and/or exercise of the Warrant. Nothing in this Section shall affect in any way the Buyer’s obligations and agreement set forth
      in Section 2(g) hereof to comply with all applicable prospectus delivery requirements, if any, upon re-sale of the Securities. If the
      Buyer provides the Company, at the cost of the Company, with (i) an opinion of counsel in form, substance and scope customary for opinions
      in comparable transactions, to the effect that a public sale or transfer of such Securities may be made without registration under the
      1933 Act and such sale or transfer is effected or (ii) the Buyer provides reasonable assurances that the Securities can be sold pursuant
      to 144, Rule 144A, Regulation S, or other applicable exemption, the Company shall permit the transfer, and, in the case of the Securities,
      promptly instruct its transfer agent to issue one or more certificates, free from restrictive legend, in such name and in such denominations
      as specified by the Buyer. The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the
      Buyer, by vitiating the intent and purpose of the transactions contemplated hereby. Accordingly, the Company acknowledges that the remedy
      at law for a breach of its obligations under this Section 5 may be inadequate and agrees, in the event of a breach or threatened breach
      by the Company of the provisions of this Section, that the Buyer shall be entitled, in addition to all other available remedies, to an
      injunction restraining any breach and requiring immediate transfer, without the necessity of showing economic loss and without any bond
      or other security being required.

   

  6. Conditions
        to the Company’s Obligation to Sell. The obligation of the Company hereunder to issue and sell the Note to the Buyer at the
      Closing is subject to the satisfaction, at or before the Closing Date, of each of the following conditions thereto, provided that these
      conditions are for the Company’s sole benefit and may be waived by the Company at any time in its sole discretion:

   

   a. The Buyer shall have executed this Agreement and delivered the same to the Company.

   

  b.
      The Buyer shall have delivered the Purchase Price in accordance with Section 1(b) above.

   

  c. The
      representations and warranties of the Buyer shall be true and correct in all material respects as of the date when made and as of the
      Closing Date, as though made at that time (except for representations and warranties that speak as of a specific date), and the Buyer
      shall have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this
      Agreement to be performed, satisfied or complied with by the Buyer at or prior to the Closing Date.

   

  d. No
      litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or
      endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
      over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

   

  7. Conditions
        to The Buyer’s Obligation to Purchase. The obligation of the Buyer hereunder to purchase the Note, on the Closing Date, is
      subject to the satisfaction, at or before the Closing Date, of each of the following conditions, provided that these conditions are for
      the Buyer’s sole benefit and may be waived by the Buyer at any time in its sole discretion:

   

   a. The Company shall have executed this Agreement and delivered the same to the Buyer.

   

  

  
  
    14

  

  
     

  

  
   

  b. The
      Company shall have delivered to the Buyer the duly executed Note in such denominations as the Buyer shall request and in accordance with
      Section 1(b) above.

   

   c. The Company shall have delivered to the Buyer the Warrant.

   

  d. The
      Irrevocable Transfer Agent Instructions, in form and substance satisfactory to the Buyer, shall have been delivered to and acknowledged
      in writing by the Company’s Transfer Agent.

   

  e. The
      representations and warranties of the Company shall be true and correct in all material respects as of the date when made and as of Closing
      Date, as though made at such time (except for representations and warranties that speak as of a specific date) and the Company shall
      have performed, satisfied and complied in all material respects with the covenants, agreements and conditions required by this Agreement
      to be performed, satisfied or complied with by the Company at or prior to the Closing Date.

   

  f. No
      litigation, statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated or
      endorsed by or in any court or governmental authority of competent jurisdiction or any self-regulatory organization having authority
      over the matters contemplated hereby which prohibits the consummation of any of the transactions contemplated by this Agreement.

   

  g. No
      event shall have occurred which could reasonably be expected to have a Material Adverse Effect on the Company including but not limited
      to a change in the 1934 Act reporting status of the Company or the failure of the Company to be timely in its 1934 Act reporting obligations.

   

  h. Trading
      in the Common Stock on the Principal Market shall not have been suspended by the SEC, FINRA or the Principal Market.

   

  i. The
      Company shall have delivered to the Buyer (i) a certificate evidencing the formation and good standing of the Company and each of its
      Subsidiaries in such entity’s jurisdiction of formation issued by the Secretary of State (or comparable office) of such jurisdiction,
      as of a date within ten (10) days of the Closing Date and (ii) resolutions adopted by the Company’s Board of Directors at a duly
      called meeting or by unanimous written consent authorizing this Agreement and all other documents, instruments and transactions contemplated
      hereby.

   

  8. Governing
        Law; Miscellaneous.

   

  a. Governing
        Law; Venue. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada without regard to
      principles of conflicts of laws. Any action brought by either party against the other concerning the transactions contemplated by this
      Agreement, the Note, or any other agreement, certificate, instrument or document contemplated hereby shall be brought only in the state
      courts located in the Commonwealth of Massachusetts or in the federal courts located in the Commonwealth of Massachusetts. The parties
      to this Agreement hereby irrevocably waive any objection to jurisdiction and venue of any action instituted hereunder and shall not assert
      any defense based on lack of jurisdiction or venue or based upon forum non conveniens. EACH PARTY HEREBY IRREVOCABLY WAIVES
        ANY RIGHT IT MAY HAVE, AND AGREES NOT TO REQUEST, A JURY TRIAL FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION WITH OR
        ARISING OUT OF THIS AGREEMENT OR ANY TRANSACTIONS CONTEMPLATED HEREBY. The prevailing party shall be entitled to recover from the
      other party its reasonable attorney’s fees and costs. Each party hereby irrevocably waives personal service of process and consents
      to process being served in any suit, action or proceeding in connection with this Agreement, the Note, or any other agreement, certificate,
      instrument or document contemplated hereby or thereby by mailing a copy thereof via registered or certified mail or overnight delivery
      (with evidence of delivery) to such party at the address in effect for notices to it under this Agreement and agrees that such service
      shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any
      way any right to serve process in any other manner permitted by law.

   

  b. Counterparts.
      This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which shall constitute
      one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party.
      A facsimile or .pdf signature shall be considered due execution and shall be binding upon the signatory thereto with the same force and
      effect as if the signature were an original, not a facsimile or .pdf signature. Delivery of a counterpart signature hereto by facsimile
      or email/.pdf transmission shall be deemed validly delivery thereof.

   

  

  
  
    15

  

  
     

  

  
   

  c. Construction;
        Headings. This Agreement shall be deemed to be jointly drafted by the Company and the Buyer and shall not be construed against any
      person as the drafter hereof. The headings of this Agreement are for convenience of reference only and shall not form part of, or affect
      the interpretation of, this Agreement.

   

  d. Severability.
      In the event that any provision of this Agreement, the Note, or any other agreement or instrument delivered in connection herewith
      is invalid or unenforceable under any applicable statute or rule of law, then such provision shall be deemed inoperative to the extent
      that it may conflict therewith and shall be deemed modified to conform with such statute or rule of law. Any such provision which may
      prove invalid or unenforceable under any law shall not affect the validity or enforceability of any other provision of this Agreement,
      the Note, or any other agreement, certificate, instrument or document contemplated hereby or thereby.

   

  e. Entire
        Agreement; Amendments. This Agreement, the Note, and the instruments referenced herein contain the entire understanding of the parties
      with respect to the matters covered herein and therein and, except as specifically set forth herein or therein, neither the Company nor
      the Buyer makes any representation, warranty, covenant or undertaking with respect to such matters. No provision of this Agreement or
      any agreement or instrument contemplated hereby may be waived or amended other than by an instrument in writing signed by the Buyer.

   

  f. Notices. All
      notices, demands, requests, consents, approvals, and other communications required or permitted hereunder shall be in writing and,
      unless otherwise specified herein, shall be (i) personally served, (ii) deposited in the mail, registered or certified, return
      receipt requested, postage prepaid, (iii) delivered by reputable air courier service with charges prepaid, or (iv) transmitted by
      hand delivery, telegram, e-mail or facsimile, addressed as set forth below or to such other address as such party shall have
      specified most recently by written notice. Any notice or other communication required or permitted to be given hereunder shall be
      deemed effective (a) upon hand delivery or delivery by e-mail or facsimile, with accurate confirmation generated by the transmitting
      facsimile machine, at the address or number designated below (if delivered on a business day during normal business hours where such
      notice is to be received), or the first business day following such delivery (if delivered other than on a business day during
      normal business hours where such notice is to be received) or (b) on the second business day following the date of mailing by
      express courier service, fully prepaid, addressed to such address, or upon actual receipt of such mailing, whichever shall first
      occur. The addresses for such communications shall be:

   

  If
      to the Company, to:

   

  GZ6G
      TECHNOLOGIES CORP.

  8925
      West Post Road, Suite 102

  Las
      Vegas, NV 89148

  Attention:
      William Smith

  e-mail:
      cole@greenzebra.net

   

  If
      to the Buyer:

   

  TALOS
      VICTORY FUND, LLC

  348
      Cambridge Street #101

  Woburn,
      MA 01801

  e-mail:
      admin@talosvf.com

   

  g. Successors
        and Assigns. This Agreement shall be binding upon and inure to the benefit of the parties and their successors and assigns. The Company
      shall not assign this Agreement or any rights or obligations hereunder without the prior written consent of the Buyer. The Buyer may
      assign its rights hereunder to any “accredited investor” (as defined in Rule 501(a) of the 1933 Act) in a private transaction
      from the Buyer or to any of its “affiliates,” as that term is defined under the 1934 Act, without the consent of the Company.

   

  h. Third
        Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective permitted successors and
      assigns, and is not for the benefit of, nor may any provision hereof be enforced by, any other person.

   

  

  
  
    16

  

  
     

  

  
   

  i. Survival.
      The representations and warranties of the Company and the agreements and covenants set forth in this Agreement shall survive the
      closing hereunder notwithstanding any due diligence investigation conducted by or on behalf of the Buyer. The Company agrees to indemnify
      and hold harmless the Buyer and all their officers, directors, employees and agents for loss or damage arising as a result of or related
      to any breach or alleged breach by the Company of any of its representations, warranties and covenants set forth in this Agreement or
      any of its covenants and obligations under this Agreement, including advancement of expenses as they are incurred.

   

  j. Publicity.
      The Company, and the Buyer shall have the right to review a reasonable period of time before issuance of any press releases, SEC,
      Principal Market or FINRA filings, or any other public statements with respect to the transactions contemplated hereby; provided,
      however, that the Company shall be entitled, without the prior approval of the Buyer, to make any press release or SEC, Principal
      Market (or other applicable trading market) or FINRA filings with respect to such transactions as is required by applicable law and regulations
      (although the Buyer shall be consulted by the Company in connection with any such press release prior to its release and shall be provided
      with a copy thereof and be given an opportunity to comment thereon).

   

  k. Further
        Assurances. Each party shall do and perform, or cause to be done and performed, all such further acts and things, and shall execute
      and deliver all such other agreements, certificates, instruments and documents, as the other party may reasonably request in order to
      carry out the intent and accomplish the purposes of this Agreement and the consummation of the transactions contemplated hereby.

   

  l. No
        Strict Construction. The language used in this Agreement will be deemed to be the language chosen by the parties to express their
      mutual intent, and no rules of strict construction will be applied against any party.

   

  m. Indemnification.
      In consideration of the Buyer’s execution and delivery of this Agreement and acquiring the Securities hereunder, and in addition
      to all of the Company’s other obligations under this Agreement or the Note, the Company shall defend, protect, indemnify and hold
      harmless the Buyer and its stockholders, partners, members, officers, directors, employees and direct or indirect investors and any of
      the foregoing persons’ agents or other representatives (including, without limitation, those retained in connection with the transactions
      contemplated by this Agreement) (collectively, the “Indemnitees”) from and against any and all actions, causes of action,
      suits, claims, losses, costs, penalties, fees, liabilities and damages, and expenses in connection therewith (irrespective of whether
      any such Indemnitee is a party to the action for which indemnification hereunder is sought), and including reasonable attorneys’
      fees and disbursements (the “Indemnified Liabilities”), incurred by any Indemnitee as a result of, or arising out of, or
      relating to (a) any misrepresentation or breach of any representation or warranty made by the Company in this Agreement, the Note or
      any other agreement, certificate, instrument or document contemplated hereby or thereby, (b) any breach of any covenant, agreement or
      obligation of the Company contained in this Agreement, the Note or any other agreement, certificate, instrument or document contemplated
      hereby or thereby or (c) any cause of action, suit or claim brought or made against such Indemnitee by a third party (including for these
      purposes a derivative action brought on behalf of the Company) and arising out of or resulting from (i) the execution, delivery, performance
      or enforcement of this Agreement, the Note or any other agreement, certificate, instrument or document contemplated hereby or thereby,
      (ii) any transaction financed or to be financed in whole or in part, directly or indirectly, with the proceeds of the issuance of the
      Securities, or (iii) the status of the Buyer or holder of the Securities as an investor in the Company pursuant to the transactions contemplated
      by this Agreement. To the extent that the foregoing undertaking by the Company may be unenforceable for any reason, the Company shall
      make the maximum contribution to the payment and satisfaction of each of the Indemnified Liabilities that is permissible under applicable
      law.

   

  n. Remedies.
      The Company acknowledges that a breach by it of its obligations hereunder will cause irreparable harm to the Buyer by vitiating the
      intent and purpose of the transaction contemplated hereby. Accordingly, the Company acknowledges that the remedy at law for a breach
      of its obligations under this Agreement, the Note, the Warrant, or any other agreement, certificate, instrument or document contemplated
      hereby or thereby will be inadequate and agrees, in the event of a breach or threatened breach by the Company of the provisions of this
      Agreement, the Note, the Warrant, or any other agreement, certificate, instrument or document contemplated hereby or thereby, that the
      Buyer shall be entitled, in addition to all other available remedies at law or in equity, and in addition to the penalties assessable
      herein, to an injunction or injunctions restraining, preventing or curing any breach of this Agreement, the Note, the Warrant, or any
      other agreement, certificate, instrument or document contemplated hereby or thereby, and to enforce specifically the terms and provisions
      hereof and thereof, without the necessity of showing economic loss and without any bond or other security being required.

   

  

  
  
    17

  

  
     

  

  
   

  o. Payment
        Set Aside. To the extent that the (i) Company makes a payment or payments to the Buyer hereunder, pursuant to the Note, pursuant
      to the Warrant, or pursuant to any other agreement, certificate, instrument or document contemplated hereby or thereby, or (ii) the Buyer
      enforces or exercises its rights hereunder, pursuant to the Note, pursuant to the Warrant, or pursuant to any other agreement, certificate,
      instrument or document contemplated hereby or thereby, and such payment or payments or the proceeds of such enforcement or exercise or
      any part thereof (including but not limited to the sale of the Securities) are for any reason (i) subsequently invalidated, declared
      to be fraudulent or preferential, set aside, recovered from, or disgorged by the Buyer, or (ii) are required to be refunded, repaid or
      otherwise restored to the Company, a trustee, receiver or any other person or entity under any law (including, without limitation, any
      bankruptcy law, foreign, state or federal law, common law or equitable cause of action), then (i) to the extent of any such restoration
      the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such
      payment had not been made or such enforcement or setoff had not occurred and (ii) the Company shall immediately pay to the Buyer a dollar
      amount equal to the amount that was for any reason (i) subsequently invalidated, declared to be fraudulent or preferential, set aside,
      recovered from, or disgorged by the Buyer, or (ii) required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver
      or any other person or entity under any law (including, without limitation, any bankruptcy law, foreign, state or federal law, common
      law or equitable cause of action).

   

  p. Failure
        or Indulgence Not Waiver. No failure or delay on the part of the Buyer in the exercise of any power, right or privilege hereunder
      shall operate as a waiver thereof, nor shall any single or partial exercise of any such power, right or privilege preclude other or further
      exercise thereof or of any other right, power or privileges. All rights and remedies of the Buyer existing hereunder are cumulative to,
      and not exclusive of, any rights or remedies otherwise available.

   

  [Signature
      Page Follows]

   

  

  
  
    18

  

  
     

  

  
   

  IN
      WITNESS WHEREOF, the undersigned Buyer and the Company have caused this Agreement to be duly executed as of the date first above written.

   

  GZ6G
      TECHNOLOGIES CORP.

   

  	By: 	 	 
	Name: 	 WILLIAM SMITH	 
	Title:	 CHIEF EXECUTIVE OFFICER	 

   

  TALOS
        VICTORY FUND, LLC

   

  	By:	 	 
	Name:  	THOMAS SILVERMAN	 
	Title: 	MEMBER	 

   

  SUBSCRIPTION
      AMOUNT:

   

  

  Principal Amount of Note:   $ 560,000.00

  Actual Amount of Purchase Price of Note:   $ 504,000.00  

   

  

  
  
    19

  

  
     

  

  
   

  EXHIBIT
      A

   

  FORM OF NOTE

   

  [attached
        hereto]

   

  

  
  
    20

  

  
     

  

  
   

  EXHIBIT
        B

   

  REGISTRATION RIGHTS

   

  All
      of the Conversion Shares and Exercise Shares shall be deemed “Registrable Securities” subject to the provisions of this Exhibit
      B. All capitalized terms used but not defined in this Exhibit B shall have the meanings ascribed to such terms in the Securities Purchase
      Agreement to which this Exhibit is attached.

   

  		1.	Piggy-Back Registration.

   

  1.1 Piggy-Back
        Rights. If at any time on or after the date of the Closing the Company proposes to file any Registration Statement under the 1933
      Act (a “Registration Statement”) with respect to any offering of equity securities, or securities or other obligations exercisable
      or exchangeable for, or convertible into, equity securities, by the Company for its own account or for shareholders of the Company for
      their account (or by the Company and by shareholders of the Company), other than a Registration Statement (i) filed in connection with
      any employee stock option or other benefit plan on Form S-8, (ii) for a dividend reinvestment plan or (iii) in connection with a merger
      or acquisition, then the Company shall (x) give written notice of such proposed filing to the holders of Registrable Securities appearing
      on the books and records of the Company as such a holder as soon as practicable but in no event less than ten (10) days before the anticipated
      filing date of the Registration Statement, which notice shall describe the amount and type of securities to be included in such Registration
      Statement, the intended method(s) of distribution, and the name of the proposed managing underwriter or underwriters, if any, of the
      offering, and (y) offer to the holders of Registrable Securities in such notice the opportunity to register the sale of such number of
      Registrable Securities as such holders may request in writing within three (3) days following receipt of such notice (a “Piggy-Back
      Registration”). The Company shall cause such Registrable Securities to be included in such registration and shall cause the managing
      underwriter or underwriters of a proposed underwritten offering to permit the Registrable Securities requested to be included in a Piggy-Back
      Registration on the same terms and conditions as any similar securities of the Company and to permit the sale or other disposition of
      such Registrable Securities in accordance with the intended method(s) of distribution thereof (with the understanding that the Company
      shall file the initial prospectus covering the Buyer’s sale of the Registrable Securities at prevailing market prices on the same
      date that the Registration Statement is declared effective by the SEC).

   

  1.2 Withdrawal.
      Any holder of Registrable Securities may elect to withdraw such holder’s request for inclusion of Registrable Securities in any
      Piggy-Back Registration by giving written notice to the Company of such request to withdraw prior to the effectiveness of the Registration
      Statement. The Company (whether on its own determination or as the result of a withdrawal by persons making a demand pursuant to written
      contractual obligations) may withdraw a Registration Statement at any time prior to the effectiveness of such Registration Statement.
      Notwithstanding any such withdrawal, the Company shall pay all expenses incurred by the holders of Registrable Securities in connection
      with such Piggy-Back Registration as provided in Section 1.5 below.

   

  1.3 The
      Company shall notify the holders of Registrable Securities at any time when a prospectus relating to such holder’s Registrable
      Securities is required to be delivered under the 1933 Act, upon discovery that, or upon the happening of any event as a result of which,
      the prospectus included in such Registration Statement, as then in effect, includes an untrue statement of a material fact or omits to
      state any material fact required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances
      then existing. At the request of such holder, the Company shall also prepare, file and furnish to such holder a reasonable number of
      copies of a supplement to or an amendment of such prospectus as may be necessary so that, as thereafter delivered to the purchasers of
      the Registrable Securities, such prospectus shall not include an untrue statement of a material fact or omit to state a material fact
      required to be stated therein or necessary to make the statements therein not misleading in light of the circumstances then existing.
      The holders of Registrable Securities shall not to offer or sell any Registrable Securities covered by the Registration Statement after
      receipt of such notification until the receipt of such supplement or amendment.

   

  1.4 The
      Company may request a holder of Registrable Securities to furnish the Company such information with respect to such holder and such
      holder’s proposed distribution of the Registrable Securities pursuant to the Registration Statement as the Company may from
      time to time reasonably request in writing or as shall be required by law or by the SEC in connection therewith, and such holders
      shall furnish the Company with such information.

   

  

  
  
    21

  

  
     

  

  
   

  1.5 All
      fees and expenses incident to the performance of or compliance with this Exhibit B by the Company shall be borne by the Company
      whether or not any Registrable Securities are sold pursuant to a Registration Statement. The fees and expenses referred to in the
      foregoing sentence shall include, without limitation, (i) all registration and filing fees (including, without limitation, fees and
      expenses of the Company’s counsel and independent registered public accountants) (A) with respect to filings made with the
      SEC, (B) with respect to filings required to be made with any trading market on which the Common Stock is then listed for trading,
      (C) in compliance with applicable state securities or Blue Sky laws reasonably agreed to by the Company in writing (including,
      without limitation, fees and disbursements of counsel for the Company in connection with Blue Sky qualifications or exemptions of
      the Registrable Securities) and (D) with respect to any filing that may be required to be made by any broker through which a holder
      of Registrable Securities intends to make sales of Registrable Securities with the FINRA, (ii) printing expenses, (iii) messenger,
      telephone and delivery expenses, (iv) fees and disbursements of counsel for the Company, (v) 1933 Act liability insurance, if the
      Company so desires such insurance, (vi) fees and expenses of all other persons or entities retained by the Company in connection
      with the consummation of the transactions contemplated by this Exhibit B and (vii) reasonable fees and disbursements of a single
      special counsel for the holders of Registrable Securities (selected by holders of the majority of the Registrable Securities
      requesting such registration). In addition, the Company shall be responsible for all of its internal expenses incurred in connection
      with the consummation of the transactions contemplated by this Agreement (including, without limitation, all salaries and expenses
      of its officers and employees performing legal or accounting duties), the expense of any annual audit and the fees and expenses
      incurred in connection with the listing of the Registrable Securities on any securities exchange as required hereunder. In no event
      shall the Company be responsible for any broker or similar commissions of any holder of Registrable Securities.

   

  1.6 The
      Company and its successors and assigns shall indemnify and hold harmless the Buyer, each holder of Registrable Securities, the officers,
      directors, members, partners, agents and employees (and any other individuals or entities with a functionally equivalent role of a person
      holding such titles, notwithstanding a lack of such title or any other title) of each of them, each individual or entity who controls
      the Buyer or any such holder of Registrable Securities (within the meaning of Section 15 of the 1933 Act or Section 20 of the 1934 Act)
      and the officers, directors, members, stockholders, partners, agents and employees (and any other individuals or entities with a functionally
      equivalent role of a person holding such titles, notwithstanding a lack of such title or any other title) of each such controlling individual
      or entity (each, an “Indemnified Party”), to the fullest extent permitted by applicable law, from and against any and all
      losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys’ fees) and expenses (collectively,
      “Losses”), as incurred, arising out of or relating to (1) any untrue or alleged untrue statement of a material fact
      contained in a Registration Statement, any related prospectus or any form of prospectus or in any amendment or supplement thereto or
      in any preliminary prospectus, or arising out of or relating to any omission or alleged omission of a material fact required to be stated
      therein or necessary to make the statements therein (in the case of any such prospectus or supplement thereto, in light of the circumstances
      under which they were made) not misleading or (2) any violation or alleged violation by the Company of the 1933 Act, the 1934 Act or
      any state securities law, or any rule or regulation thereunder, in connection with the performance of its obligations under this Exhibit
      B, except to the extent, but only to the extent, that (i) such untrue statements or omissions are based upon information regarding the
      Buyer or such holder of Registrable Securities furnished to the Company by such party for use therein. The Company shall notify the Buyer
      and each holder of Registrable Securities promptly of the institution, threat or assertion of any proceeding arising from or in connection
      with the transactions contemplated by this Exhibit B of which the Company is aware.

   

  

  
  
    22

  

  
     

  

  
   

  1.7 If
      the indemnification under Section 1.6 is unavailable to an Indemnified Party or insufficient to hold an Indemnified Party harmless
      for any Losses, then the Company shall contribute to the amount paid or payable by such Indemnified Party, in such proportion as is
      appropriate to reflect the relative fault of the Company and Indemnified Party in connection with the actions, statements or
      omissions that resulted in such Losses as well as any other relevant equitable considerations. The relative fault of the Company and
      Indemnified Party shall be determined by reference to, among other things, whether any action in question, including any untrue or
      alleged untrue statement of a material fact or omission or alleged omission of a material fact, has been taken or made by, or
      relates to information supplied by, the Company or the Indemnified Party, and the parties’ relative intent, knowledge, access
      to information and opportunity to correct or prevent such action, statement or omission. The amount paid or payable by a party as a
      result of any Losses shall be deemed to include any reasonable attorneys’ or other fees or expenses incurred by such party in
      connection with any proceeding to the extent such party would have been indemnified for such fees or expenses if the indemnification
      provided for in Section 1.6 was available to such party in accordance with its terms. It is agreed that it would not be just and
      equitable if contribution pursuant to this Section 1.7 were determined by pro rata allocation or by any other method of allocation
      that does not take into account the equitable considerations referred to in the immediately preceding sentence. Notwithstanding the
      provisions of this Section 1.7, neither the Buyer nor any holder of Registrable Securities shall be required to contribute, in the
      aggregate, any amount in excess of the amount by which the net proceeds actually received by such party from the sale of all of
      their Registrable Securities pursuant to such Registration Statement or related prospectus exceeds the amount of any damages that
      such party has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged
      omission.

   

  [End
      of Exhibit B]

   

  

  
  
    23

  

  
     

  

  
   

  Exhibit
      C

   

  Registration
      Rights Agreement

   

  (see
      attached)

   

  

  
  
    24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00339-of-00352.parquet"}]]